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ABSTRACT 
Antibodies specific for DEC205, a dendritic cell (DC) endocytic receptor 
that traffics to the antigen presentation pathway, have been shown to be 
excellent tools for raising robust, sustained immune responses to co-delivered 
vaccine antigens; however, strong immune responses are only elicited with the 
aid of non-specific dendritic cell maturation factors, without which a tolerogenic 
immune response is induced. We hypothesize that regulatory T cell epitopes 
(Tregitopes) located in the αDEC205 sequence promotes tolerance, requiring 
the use of non-specific immuno-stimulators to promote pro-inflammatory 
immune responses. This hypothesis is based on previous research performed 
by De Groot et al. 2008 who characterized a set of natural regulatory T cell 
epitopes derived from human immunoglobulins (IgG) that were found to induce 
tolerance by stimulating regulatory T cells (CD4+CD25+FoxP3+). 
We believe that αDEC205 can be rendered less tolerogenic by modifying 
its regulatory T cell epitope content and improve its capacity to induce 
inflammatory responses without the aid of non-specific maturation factors to 
activate the immune system. 
In this work, the αDEC205 sequence was computationally screened for 
putative HLA-Class II-restricted, regulatory T cell epitopes as targets for 
elimination by mutation. Mutations affecting key amino acid sites, relevant to 
peptide-HLA-DRB1*0401 binding, were carried out to reduce epitope binding 
affinity to the HLA-DRB1*0401 allele. Sequence modifications confirmed to 
 disrupt peptide-HLA binding were incorporated into an array of 
αDEC205:OVA-ORG (original sequence) variants (mutant sequences) via site 
directed mutagenesis. Protein was produced by CHO-S cell transient 
transfection. Purified variant αDEC205:OVA-ORG recombinant proteins were 
utilized in DR4 in vivo immunizations and functional assays to observe T cell 
activation and proliferative immune responses. 
The αDEC205:OVA variants (HC54-MOD1, VH77-MOD1 & VH77-
MOD2) were shown to target and bind to dendritic cells as effectively as the 
non-modified αDEC205:OVA antibody. Splenocytes were re-stimulated with 
ovalbumin in the T cell proliferation assay and with OVA Class I (257-264) and 
OVA Class II (323-339) peptides in the ELISpot assay to measure the memory 
responses. Both αDEC205:OVA-VH77-MOD1 and αDEC205:OVA-VH77-
MOD2 showed statistically significant differences in CD8+ and CD4+ T cell 
proliferation in comparison to splenocytes previously immunized with the 
αDEC205:OVA-ORG antibody condition, respectively. However, a lack of 
statistically significant IFN-γ cytokine production was observed for all variant 
antibody immunization conditions. Further analyses are required to determine 
the true significance observed from the αDEC205:OVA-VH77-MOD1 data set 
as evidenced by the possible outliers, which may be skewing the results. The 
αDEC205:OVA-HC54-MOD1 sequence failed to generate elevated levels of T 
cell proliferation and IFN-γ secretion responses.  
It was concluded that the αDEC205:OVA antibodies (VH77-MOD1 and  
VH77-MOD2) induced statistically significant elevated T cell proliferative 
 responses in comparison to the baseline immune response levels of the non-
modified αDEC205:OVA-ORG antibody, suggesting that an improved vaccine 
delivery system is underway due to the epitope modifications at the VH77 
Tregitope sequence, which potentially decreased the tolerogenicity of the 
αDEC-205:OVA antibody. In regards to the other variant antibodies, further 
modifications to the Tregitope sequences in the αDEC205:OVA antibody’s 
overall sequence may be necessary to reduce tolerogenicity further to begin to 
create a detolerized antibody capable of inducing a pro-inflammatory immune 
response without the aid of a non-specific immuno-stimulator. 
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CHAPTER 1 
 
INTRODUCTION 
 
 Since their discovery in 1973, dendritic cells (DCs) have proven to be 
specialized immune cells and potent stimulators of primary immune responses 
(Hart, 1997, Janeway et al. 2001, Granucci et al. 2005, Lipscomb et al. 2002). 
Initial interest peaked when these bone marrow-derived cells were found to be 
not only in mice, but also in most human lymphoid (spleen, thymus, and lymph 
nodes) and non-lymphoid tissue (Hart, 1997, Lipscomb et al. 2002). 
Information regarding DCs has only continued to grow, leading to the 
knowledge that DCs play a central role in the immune system by controlling 
both immune tolerance and immunity (Palucka et al. 2002, Granucci et al. 
2005, Ueno et al. 2007, Steinman et al. 2006). Because of these qualities, 
researchers are considering DCs as viable candidates to contribute to the 
improvement of targeted vaccine delivery platform systems (Palucka et al. 
2002, Hart, 1997, Tacken et al. 2007).  
Myeloid lineage DCs originate from bone marrow and are a part of a 
specific sub-population of cells (professional antigen presenting cells) (APCs), 
which comprise both Macrophages and B cells (Chaterjee et al. 2012, Hart, 
1997, Nagl et al. 1997, Steinman et al. 2006). A primary function of DCs is to 
alert the immune system to any invading organism they may potentially 
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encounter (Janeway et al. 2001). Thus, APCs’ antigen uptake process is an 
essential and critical function of the immune system (Steinman et al. 2006, 
Hart, 1997, Lipscomb et al. 2002). These cells efficiently process antigen, and 
present it in peptide-form in context of up-regulated MHC complexes (Hart, 
1997, Steinman et al. 2006, Steinman et al. 2000, Janeway et al. 2001). 
Antigen-uptake facilitates directed antigen-specific T cell mediated immune 
responses, leading to the initiation of an adaptive immune response, a more 
specific and targeted immune response (Steinman et al. 2000, Hart, 1997, 
Janeway et al. 2001, Male et al. 2006, Wilson et al. 2004, Tacken et al. 2007, 
Bonifaz et al. 2002).  
In order for DCs to perform this task, immature DCs circulate along the 
tissue periphery, efficiently and continuously sampling their environment for 
antigen in a variety of manners: phagocytosis of particles, fluid phase 
macropinocytosis, receptor-mediated endocytosis, or direct contact with 
apoptotic or infected cells (Nagl et al. 1997, Steinman et al. 2006, Hart, 1997). 
Following the antigenic encounter, peripheral-immature DCs process and 
present the antigen in peptide-form on DCs surfaces. Immature DCs express a 
variety of CLRs that are down regulated after maturation (Tel et al. 2011).  
Immature DCs then travel from the tissue periphery via the lymphatic 
system to the nearest draining-lymph node, a secondary lymphoid organ, only 
after receiving appropriate direct-pathogenic signals or environmental 
inflammatory stimuli, causing the up-regulation of cell surface-chemokine 
receptors and subsequent DC migration (Hart, 1997, Nagl et al. 1997). Within 
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lymph nodes, the site of antigen localization, naive T cells are exposed to 
antigenic peptides by mature DCs. Mature DCs then acquire the ability to 
activate and facilitate naïve T cell polarization; a hallmark of mature DCs, 
resulting in an antigen-specific T cell mediated immune response (Steinman et 
al. 2000, Hart, 1997, Tel et al. 2011).  
 Since DCs can play a role in both innate and adaptive immunity, their 
uniqueness as nature’s adjuvant has attracted the attention of the scientific 
community (Steinman et al. 2000, Steinman et al. 2007, Nagl et al. 1997, 
Masten et al. 2006). As such, researchers have begun taking advantage of 
their functional roles within the immune system as vaccine targets for 
therapeutic antibodies (Chames et al. 2009, Dimitrov et al. 2010). Because of 
the roles DCs play and their natural propensity for receptor-mediated 
endocytosis, it only seems fitting for therapeutic antibodies to be viewed as a 
viable option for therapy against the human immuno-deficiency virus (HIV), 
cancer, and other autoimmune diseases; researchers have even considered it 
to be a viable delivery vehicle in cases of cancer (Tacken et al. 2007, Dimitrov 
et al. 2010, Steinman et al. 2006, Steinman et al. 2000, Kreutz et al. 201). 
These therapeutic targeting antibodies have demonstrated moderate success 
in past clinical trials (Tacken et al. 2007, Steinman et al. 2006).  
A monoclonal antibody (mAb) that has proven to be effective in raising 
robust and sustained immune responses is the αDEC-205 antibody (Boscardin 
et al. 2006). In past in vitro research, the αDEC-205 antibody has proven a 
capable delivery vehicle of tumor antigen that showed to elicit broad range 
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antigen specificity (Tsuji et al. 2010). Due to its targeting abilities, the αDEC-
205 antibody elicits sustained immune responses to co-delivered vaccine 
antigens (Bonifaz et al. 2002, Bonifaz et al. 2004, Bozzaco et al. 2007, Tacken 
et al. 2007, Jiang et al. 1995, Mahnke et al. 2000, Boscardin et al. 2006). 
During immunizations, this antibody, when co-delivered with antigen, targets 
the DEC-205 endocytic receptor that internalizes the antibody-antigen 
complex (Bonifaz et al. 2002, Bozzaco et al. 2007, Mahnke et al. 2000). DCs 
display the processed antibody-antigenic peptides in the Major 
Histocompatibility Complex (MHC) molecule’s binding groove on the cell’s 
surface for presentation to specific CD4+ T cells (Steinman et al. 2000, Koren 
et al. 2007). When CD4+ T cells bind to the peptide-MHC complex, this forms 
the immunological synapse, a key interaction between DCs and T cells that 
initiate the adaptive immune response (Janeway et al. 2001, Male et al. 2006). 
As the adaptive immune response is called into action, two types of immune 
responses can be induced: either a tolerogenic or an effector-pro-inflammatory 
immune response (Janeway et al. 2001, Male et al. 2006). 
  In previous BALB/C-C57BL/6 mice immunizations involving αDEC-
205:OVA antibody absent of co-stimulatory molecules, a tolerogenic immune 
response was observed in both in vitro and ex vivo cultures (Bonifaz et al. 
2002). Further studies confirmed that the tolerogenic immune response was 
not induced due to the attached vaccine antigen, ovalbumin. The results 
showed that even when the αDEC-205 antibody was coupled with various 
antigens, the tolerogenic immune response remained induced because a co-
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stimulatory molecule was not present during immunizations (Bonifaz et al. 
2002, Bonifaz et al. 2004, Tacken et al. 2007, Matos et al. 2013). This 
suggested that the antibody itself, rather than the various attached antigens, 
induced the tolerogenic immune response. Strong inflammatory T cell 
responses were only generated with co-administration of a maturation factor 
(αCD40) or adjuvant (Steinman et al. 2000, Bonifaz et al. 2002, Matos et al. 
2013)  
 The tolerogenicity finding is well supported by De Groot et al. (2008) 
who demonstrated that the presence of T-regulatory cell epitope sequences 
(Tregitopes) within antibody sequences activates regulatory T cells (Tregs) 
(modulators of the immune system that prevent it from reacting against self-
antigen by readily inducing a tolerogenic immune state) (Josefowicz et al. 
2012, Cousens et al. 2013). De Groot and colleagues hypothesized that 
various natural T regulatory cell epitopes that are highly conserved amongst 
human and mouse Immunoglobulin G (IgG) cause the tolerogenic effect (De 
Groot et al. 2008, De Groot et al. 2013). When those particular sequences 
were presented, an increase in regulatory T cell expansion 
(CD4+CD25+FoxP3+) and activation was detected in studies involving 
Tregitope stimulation of peripheral blood mononuclear cells (PBMCs) (De 
Groot et al. 2008, De Groot et al. 2013). It is these Tregitopes within α-DEC-
205’s antibody sequence that are thought to promote tolerance and require 
the use of a non-specific immuno-stimulator. If the Tregitopes can be located 
and modified, it is then possible that the αDEC-205:OVA antibody may be 
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rendered less tolerogenic, thereby improving its capacity to induce a pro-
inflammatory immune response without non-specific activation of the immune 
system. This is a novel approach that has not been performed prior. 
The purpose of this study is to locate and modify tolerogenic Tregitopes 
within the αDEC-205 sequence, to prevent them from being presented on 
MHC molecules and subsequently induce a Treg suppressive immune 
response. Criteria pre-determined by in silico algorithmic tools identifies MHC-
II restricted, putative T cell epitope sequences and generates suggested 
amino acid modifications to the targeted T cell epitopes in order to reduce 
binding potential to the MHC-II molecules. Suggested modifications are then 
incorporated into full-length variant αDEC-205:OVA-ORG (original) antibodies. 
These variant αDEC-205:OVA antibodies are then tested in an array of 
memory response-immunogenicity assays to determine if the variant 
antibodies can induce greater levels of pro-inflammatory immune responses, 
rendering each antibody less tolerogenic due to the specific modifications 
applied to each antibody’s specific Tregitope sequence. These modifications 
would lead to an improved DC-targeted vaccine platform system that could 
potentially safely and effectively deliver vaccine test antigens to target T cells 
by way of the DEC-205 endocytic receptor, found ubiquitously on DCs 
(Steinman et al. 2000, Bonifaz et al. 2002, Bonifaz et al. 2004, Tacken et al. 
2007). 
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
Dendritic cells and the Host Defense  
A functional priority of immature DCs is to capture antigen, found while 
patrolling the periphery, and relay acquired processed antigenic peptides to 
naïve T cells (Steinman et al. 2000, Lipscomb et al. 2002, Hart, 1997, 
Janeway et al. 2001, Tacken et al. 2007, Wilson et al. 2004). Immature DCs 
require specialized receptors to recognize and capture antigen (Steinman et 
al. 2000, Lipscomb et al. 2002, Hart, 1997, Janeway et al. 2001, Wilson et al. 
2004). During an infection, DCs are attracted to sites of inflammation via 
environmental stimuli, where the processes of engulfing invading 
microorganisms, foreign bodies, or apoptotic self-tissues via phagocytosis and 
endocytosis occur (van Vliet et al. 2007, van Vliet et al. 2008, Lipscomb et al. 
2002). To defend the host and opsonize pathogens, DCs use pattern 
recognition receptors (PRR) that are highly evolutionarily conserved, germline-
encoded receptors, expressed on DC cell surfaces (Kerrigan et al. 2011, 
Wilson et al. 2004, Pyz et al. 2006). These PRRs recognize characteristics 
specific to bacterial or viral components known as pathogen-associated 
molecular patterns that include lipopolysaccharides and peptidoglycans 
(PAMPs) (van Vliet et al. 2007, Pyz et al. 2006, Kerrigan et al. 2011, Granucci 
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et al. 2005). PRRs are present in high quantity on immature DCs and are most 
notably represented by Toll-like receptors (TLRs) and C-type lectin receptors 
(CLRs) (Pyz et al. 2006, van Vliet et al. 2007 den Dunnen et al. 2012, Wilson 
et al. 2004). PRR activation leads to intracellular signaling and triggers innate 
immunity, initiating a cascade of events that include secretion of cytokines and 
the up-regulation of cell surface receptors, which further define the process of 
DC maturation and T cell interaction (Granucci et al. 2005, Kerrigan et al. 
2011, Steinman et al. 2001, Tacken et al. 2007, Hart, 1997, van Vliet et al. 
2007, Wilson et al. 2004). Ultimately, this process results in a DC-tailored 
pathogen-specific adaptive immune response that leads to modulation of 
subsequent cellular and humoral immune responses (Ueno et al. 2007, Kreutz 
et al. 2012, Granucci et al. 2005, Kerrigan et al. 2011, Tacken et al. 2007, 
Geijtenbeek et al. 2009, Steinman et al. 2000, Wilson et al. 2004). 
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C-type Lectin Receptors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both TLRs and CLRs are crucial for DC recognition of pathogen and 
damaged self-tissue, as well as in “self-homeostasis”  (Kerrigan et al. 2011, 
van Vliet et al. 2007, Steinman et al. 2000, Steinman et al. 2006, Van Kooyk et 
al. 2008). CLRs, in particular, represent a large superfamily of membrane-
associated DC surface-protein receptors that share primary structural 
homology in the carbohydrate-recognition domains (CRD) (Varki et al. 2009, 
Kerrigan et al. 2011, van Vliet et al. 2007). Further CLR classification is 
decided by the consensus, primary-protein sequence, a 115-130 amino acid 
Figure 1. A dendritic cell and its various C-type lectin receptors 
(CLRs). These receptors can be found on various subsets of 
DCs. C-type lectin receptors mainly bind to carbohydrate 
moieties specific to pathogens, such as peptidoglycan. This 
recognition process is mediated by the carbohydrate recognition 
domains and is Ca2+ dependent, a hallmark of classical CLRs. 
Image provided from Figdor et al. 2002. 
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length sequence, found within the folded lectin domain of the CRD that 
primarily determines carbohydrate-binding specificity (van Vliet et al. 2007, 
Varki et al. 2009, Hart, 1997, Wilson et al. 2004). Numerous pathogens 
express cell-surface carbohydrate structures that function as pathogen-
specific “sugar-fingerprints” that the CLRs, mediated by the CRD, recognize in 
a calcium dependent manner, a hallmark of classical CLRs (den Dunnen et al. 
2012, Pyz et al. 2006, Hart, 1997, Varki et al. 2009).  
Immature DCs express a variety of CLRs; classic examples are the 
Mannose receptors (MR) (CD206), DEC-205 receptors (CD205), Dectin-1 and 
Dectin-2 receptors, DC-SIGN, Mincle, and asialoglycoprotein receptors (Figure 
1) (Tacken et al. 2007, Tel et al. 2011, van Vliet et al. 2007, den Dunnen et al. 
2012, Mahnke 2000, Idoyaga et al. 2008). All of these receptors have the 
capacity to capture glycosylated antigen and mediate interactions between 
specific pathogens and tailor immune responses (Van Kooyk et al. 2008, 
Tacken et al. 2007, Steinman et al. 2000, Tel et al. 2011, Wilson et al. 2004).  
 
The Multi-lectin DEC-205 Receptor  
Several CLRs have demonstrated the proclivity to not only capture 
specific antigen, triggering an innate immune response, but also facilitate 
efficient loading of antigen onto MHC Class I and Class II molecules (Rutella 
et al. 2006, Lipscomb et al. 2002, Hart, 1997, Tacken et al. 2007, van Vliet et 
al. 2007, den Dunnen et al. 2001, Idoyaga et al. 2008). Thus, CLRs have been 
explored as target receptors for targeted antigen delivery via antibodies 
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(Kreutz et al. 2012). One receptor in particular that shows such functional 
tendencies is the DEC-205 receptor (Tacken et al. 2007, van Vliet et al. 2007, 
Lahoud et al. 2012, Kreutz et al. 2012).  
The DEC-205 receptor is a C type-1 multi-lectin endocytic receptor that 
is found ubiquitously on DC surfaces; however, they are also found on various 
immune cells such as macrophages, B cells, and T cells at varying levels of 
expression dependent on cell-state maturation (Shrimpton et al. 2009, 
Steinman et al. 2006, Bonifaz et al. 2004, Mahnke et al. 2000, Tacken et al. 
2007, Lahoud et al. 2012, Caminischi et al. 2012, Kato, 2006). DEC-205 is a 
205 kD integral membrane protein receptor, homologous to the macrophage 
mannose receptor, that has a cysteine-rich domain, a fibronectin type II 
domain, and 10 extracellular, contiguous, C-type lectin-like domains (Lahoud 
et al. 2012, Mahnke, 2000). The DEC-205 receptor binds to specific-
pathogenic carbohydrate moieties in a calcium dependent manner, and takes 
part in the receptor-mediated endocytic process (Tel et al. 2011, van Vliet et 
al. 2007, Steinman et al 2006, Geijtenbeek et al. 2009). Within the DEC-205 
receptor’s distinct distal region of the cytosolic tail is an internalization 
sequence (requisite coated pit localization sequence) consisting of an acidic 
EDE triad, which facilitate receptor-mediated endocytosis and efficient 
recycling through late endosomal/lysosomal compartments (Lahoud et al. 
2012 Jiang et al. 1995, Varki et al. 2009, Geijtenbeek et al. 2009, Steinman et 
al. 2000, Mahnke et al. 2000).  
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Immunotherapy - Targeted antibodies 
There have been a number of treatment options such as surgery, 
chemotherapy, or pharmaceutical drugs over the years to try and treat most 
forms of autoimmune diseases, tumors, and cancers (Tacken et al. 2007, 
Steinman et al. 2000). However, within the past decade, immunotherapy has 
started to increase in popularity and become a viable option for disease 
treatment. In immunotherapy, a body’s own immune system is used to help 
fight off infection and disease (Lipscomb et al. 2002, Tabrizi et al. 2006). For 
example, either immune system’s cells are used to elicit a general immune 
response or mAbs are used to induce an antigen-specific immune response 
(Lipscomb et al. 2002, Tacken et al. 2007, Steinman et al. 2000, Tabrizi et al. 
2006). Cellular-based immunotherapy clinical studies, for example, utilize 
autologous DCs, ex vivo cultured, which are stimulated and loaded with tumor-
lysate antigen (Tacken et al. 2007). These DCs are then re-introduced to 
patients as a form of cellular vaccination against tumors (Tacken et al. 2007, 
Steinman et al. 2000). 
 A benefit to this type of vaccination is that cells are stimulated outside 
of the body, preventing non-specific systemic activation often associated with 
most vaccines and attributed to the harmful side effects of vaccines, ranging 
from soreness at the injection site to systemic distress (Stills et al. 2007, 
Tacken et al. 2007). However, there are limitations associated with cellular-
based immunotherapy: availability of readily isolated DC subsets or 
precursors, isolation of a sufficient number of DCs, in vitro culture capacity of 
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isolated subsets, and DC distribution once administered to the patient (Tacken 
et al. 2007).  
Those limitations and the need for an improved approach lead to the 
development of antibody targeted immunotherapy against autoimmune 
diseases, the human immunodeficiency virus (HIV), and cancers (Steinman et 
al. 2000, Tacken et al. 2007, Lahoud et al. 2012, Lipscomb et al. 2002, Rutella 
et al. 2006, Pyz et al. 2006, Bonifaz et al. 2004). Given the unique roles DCs 
play in innate and adaptive immunity and the various cell surface receptors 
found on DCs capable of endocytotic processes, strident efforts were made to 
harness and utilize DCs to develop a novel immuno-therapeutic vaccine 
strategy involving targeted delivery of antigens to resident DCs (Steinman et 
al. 2000, Tacken et al. 2007, Rutella et al. 2006, Tel et al. 2007, Boscardin et 
al. 2006). This approach became a viable option in patient care because 
mAbs’ provide beneficial vaccine specificity, which directly target the choice-
receptor, requiring less dosage of antigen, and as a result lessens the harmful 
impact of non-specific activation (Tacken, Steinman, Chan, 2010, Rutella et al. 
2006, Pyz et al. 2006, Torchillin et al. 2003, Tabrizi et al. 2006).  
Proof of principle-clinical trials reported that initial targeting of DCs by 
mAbs in vivo lead to favorable ex vivo immune responses once autologous 
DCs were re-stimulated with antigen (Tacken et al. 2007). Further studies 
reported the same results, that mAbs are capable of effectively targeting 
specific receptors for uptake of antigen and immunize against a specific 
pathogen, though in some cases immune responses were reported to be 
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limited in regards to various forms of cancer and tumors (Tacken et al. 2007, 
Lipscomb et al. 2002, Bonifaz et al. 2004, Steinman et al. 2000, Singh et al. 
2012). Reports also indicated that targeting antigen to DCs in vivo not only 
showed cellular immune responses, but also a boost in humoral immune 
responses (Caminschi et al. 2012).  
 
αDEC-205 Antibody  
Past studies showed that the DEC-205 receptor is an effective 
endocytic receptor capable of internalizing targeted antigen with subsequent 
presentation of antigen on MHC molecules, on the DC surface, to CD4+ and 
CD8+ T cells (Bonifaz et al. 2002, Steinman et al. 2006, Tacken et al. 2007, 
Caminschi et al. 2012, Corbett et al. 2012, Boscardin et al. 2006, Kato, 2006). 
Previous studies have shown that antigen targeted to the DEC-205 receptor is 
two orders of magnitude more effective at inducing T cell proliferation and IFN-
γ secretion rather than non-targeted antigens (Boscardin et al. 2006). Thus, a 
therapeutic antibody capable of targeting the DEC-205 receptor was selected 
to move forward with. αDEC-205:OVA (original) (ORG) is a chimeric mAb that 
has a rat variable region and a mouse constant region. It is a recombinant 
fusion protein with full-length ovalbumin whole protein attached to both ends of 
the αDEC-205 antibody’s heavy chains. Ovalbumin is a known mouse 
immunogen that readily induces antigen-specific cellular and humoral 
mediated immune responses (Sun et al. 2010). Nevertheless, the αDEC-205 
antibody is like any other IgG molecule containing both a F’ab (antigen binding 
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fragment) and Fc region (fragment crystallizable region) that consists of four 
polypeptide chains: two light chains and two heavy chains, each with their own 
constant and variable regions and connected by disulfide bonds (Janeway et 
al. 2001, Kumagai et al. 2001).  
 
MHC Class II Processing Pathway 
 
 
 
 
 
 
 
 
 
 
Previous research has shown the αDEC-205:OVA antibody to directly 
target the DEC-205 endocytic receptor, found ubiquitously on dendritic cells, 
where after receptor-mediated endocytosis occurs (Mahnke et al. 2000, 
Figure 2. The Class I and Class II antigen-presentation pathways 
found in all dendritic cells. The MHC I molecule presents 
peptides that are derived from endogenous proteins that are 
degraded generally in the cytosol. The MHC II molecule presents 
peptides that are derived from exogenous protein and degraded 
by proteolytic enzymes within endosomal compartments.  
Image provided by Villadangos et al. 2007.  
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Steinman et al. 2006, Tacken et al. 2007, Nagl et al. 2002, Bonifaz et al. 
2002). Following the receptor-ligand internalization, the antibody-antigen 
complex is loaded into a late endosome, which initiates the Major 
Histocompatibility Complex Class II (MHC II) processing pathway (Steinman et 
al. 2000, Bonifaz et al. 2004, Tacken et al. 2007, Holling et al. 2004, Mahnke 
et al. 2000). The DEC-205 receptor facilitates the targeting of late endosomes 
to load the receptor-ligand complex, due to the coated pit localization 
sequence in the cytosolic tail (Lahoud et a. 2012, Jiang et al. 1995). The late 
endosomes are specific to the MHC II pathway and eventually fuse with 
lysosomes containing internal proteases (Janeway et al. 2001, Male et al. 
2006, Lahoud et al. 2012, Bonifaz et al. 2002, Steinman et al. 2007). The low 
pH of the vesicle enables the antibody-antigen complex to dissociate from the 
DEC-205 receptor and proteolytic processing begins, generating antibody and 
antigenic peptide fragments (Janeway et al. 2001, Mahnke et al. 2000, Tacken 
et al. 2007, Lahoud et al. 2012, Bonifaz et al. 2002, Steinman et al. 2006, 
Varki et al. 2009). Concurrently, MHC II formation initiates in the Endoplasmic 
Reticulum (ER) (Male et al. 2006, Janeway et al. 2001).  
There are two types of MHC molecules, Class I (MHC I) and Class II 
(MHC II) (Janeway et al. 2001). Both are uniquely inherited proteins and are 
the ultimate molecules presenting the peptide fragments generated through 
the MHC processing pathway (Janeway et al. 2001). The type of antigen 
engulfed (viral, bacterial) and its location to the cell (extracellular, intracellular) 
determines which of the two MHC molecules is used and which pathway 
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(Class I or Class II) to initiate (Janeway et al. 2001, Male et al. 2006). The 
MHC I molecule generally deals with intracellular antigens such as virus 
infected cells, while MHC II molecules generally present peptides from 
extracellular proteins, such as from bacteria (Janeway et al. 2001, Steinman et 
al. 2000, Mahnke et al. 2000). Since an extracellular antibody-antigen protein 
is targeting the DC, an MHC II molecule will present the peptide fragments 
(Figure 2) (Janeway et al. 2001).  
An MHC II molecule is a cell surface protein heterodimer with 2 
homogenous polypeptide chains (α, β) consisting of 2 intracellular, trans-
membrane, and extracellular domains (Mangalam et al. 2013). The 2 
extracellular polymorphic domains (α1, β1) result in the formation of the open-
ended antigenic peptide-binding groove (Mangalam et al. 2013, Janeway et al. 
2001). For the MHC II molecule, there are 3 pairs of α- and β-chain genes, 
called HLA-DR, -DP, and –DQ (Janeway et al. 2001, Male et al. 2006). With 
several possibilities of different genes for each MHC II molecule, an individual 
is capable of recognizing and presenting a broader range of antigenic peptides 
(Janeway et al. 2001). The MHC II in humans is referred to as Human 
Leukocyte Antigen (HLA) complex and H-2 in mice (Janeway et al. 2001).  
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During this MHC II processing pathway, while the MHC II forms in the 
ER, an invariant (li) chain also forms (Janeway et al. 2001, Male et al. 2006). 
The li is ultimately situated in the MHC II peptide-binding groove, and acts as a 
chaperone-peptide throughout the MHC II molecule’s travel to the Golgi 
apparatus (Janeway et al. 2001). The li chain forms a core trimer that 
associates with the 3 MHC II αβ subunit-dimers and results in a nonameric 
complex incapable of binding antigenic peptides, which is important since 
endogenous peptide fragments are present in the ER during the MHC II 
formation (Yan et al. 2003).  
The li chain secures the MHC II’s peptide binding groove and the MHC 
Figure 3. Peptide bound to an MHC II molecule. This is a top view of 
a MHC II molecule with a specific peptide antigen (Influenza HA 
peptide 3006-318) bound in the MHC II molecule’s binding groove. 
Key peptides can be seen anchoring the peptide into the binding 
groove. This peptide-MHC complex is displayed on the dendritic cell 
surface for presentation to naïve T cells in the lymph nodes. Image 
from Neefjes and Ovaa, 2013.  
  19 
II-li complex undergoes extensive glycosylation to reach the late 
endosomal/lysosomal’s vesicle antigen processing compartments after leaving 
the Golgi apparatus (Yan et al. 2003, Janeway et al. 2001). A series of highly 
regulated proteolytic cleavages along with a HLA-DM accessory protein 
catalyzes the final release of the last li chain fragment, altogether known as 
the Class II associated invariant peptide (CLIP), and facilitates the binding of 
antigen to the binding groove (Yan et al. 2003). With the li chain removed, the 
MHC II peptide-binding groove presents specific antigenic peptide fragments 
(Yan et al. 2003, Mahnke et al. 2000). 
 The crystal structure of an MHC II shows that the antigenic peptide-
binding groove can accommodate peptide fragments between 12-25 amino 
acids in length (De Groot et al. 2008, Mangalam et al. 2013). The core 9mer 
peptide binds non-covalently, but is held in place at key anchor sites within the 
binding groove (positions 1, 4, 6, and 9) (De Groot et al. 2008, Mangalam et 
al. 2013, Male et al. 2006). Peptides are chosen based on stability, charge, 
and binding affinity to the MHC II molecule (De Groot et al. 2008, Mangalam et 
al. 2013, Parker et al. 2010, De Groot et al. 2009). The peptide-MHC II 
formation results in a stable complex that travels to the DC surface for 
presentation to its target cell population, CD4+ T cells (Holling et al. 2004, 
Steinamn et al. 2000, Yan et al. 2003, Mahnke et al. 2000).  
 
DC Migration 
Now DCs undergo a maturing differentiation process, which is 
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facilitated by the uptake of antigen and subsequent generation of peptides 
(Steinman et al. 2000, Steinman et al. 2007, Tacken et al. 2007, Lahoud et al. 
2012, Wilson et al. 2003). Antigen processing primes the immature DCs to 
initiate intracellular signaling, secrete cytokines, modulate cell surface receptor 
expression, and further signals the DCs to migrate from the tissue periphery 
via the lymphatic system to the draining lymph node, the site of antigen 
localization and naïve T cell priming (Steinman et al. 2007, Janeway et al. 
2001, Lahoud et al. 2012, Lipscomb et al. 2002, Mahnke et al. 2003). During 
this process, immature DCs outwardly change their appearance to possess 
more finger-like structures that protrude from the main body to increase 
surface area multifold; this morphological change better represents their new 
primary role of antigen presentation via MHC molecules (Lipscomb et al. 2002, 
Bonifaz et al. 2002, Steinman et al. 2006, Tacken et al. 2007, Wilson et al. 
2003).  
Immunological Synapse (IS) 
 Once DCs mature, up-regulation of various “signaling” molecules, 
representative of the current cell state appear, such as increased expression 
of MHC molecules, cell surface receptors (CD80, CD86, CD40), secretion of 
chemokines and cytokines, and adhesion molecules (Steinman et al. 2000, 
Lahoud et al. 2012, Lipscomb et al. 2002, Tacken et al. 2007). The current 
state of cellular and environmental affairs is represented by the critical 
expression of these molecules and is meant to inform other immune cells, 
especially T cells whilst the DC is in the lymph node (Steinman et al. 2000, 
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Janeway et al. 2001). The naïve T cells present in the lymph node are 
continuously circulating around the DCs, searching for antigenic peptides that 
are displayed on MHC II molecules (Steinman et al. 2000).  
T cells contain on their surface T cell receptors (TCRs), which are cell 
surface disulfide-linked heterodimer receptors similar to the antibody’s F’ab 
region (Broere et al. 2011, Janeway et al. 2001, Rudolph et al. 2006). At any 
one time, approximately 30,000 TCRs are present on the T cell’s surface with 
the majority of TCRs containing a α and β chain (Janeway et al. 2001). 
Antigen specificity is determined by TCRs, which recognize and bind to 
specific peptides presented by the MHC II molecules, on DC surfaces (Broere 
et al. 2011). However, T cells are only capable of recognizing peptides if they 
are apart of the peptide-MHC complex (Figure 5) (Broere et al. 2011, 
Josefowicz et al. 2012, Janeway et al. 2001). T cell lineage-specific accessory 
molecules and adhesion molecules bind to DCs (CD4 or CD8) and facilitate 
the process by providing stability to the DC-T cell interaction (Janeway et al. 
2001, Broere et al. 2011). Nonetheless, immediately after binding, the naïve T 
cell initiates a cascade of events, such as intracellular signaling with -function-
associated protein 1 (LFA-1) and the intracellular adhesion molecule 1 (ICAM-
1), up-regulates and modulates cell surface receptors (CD28) (CTLA-4), and 
secretes cytokines and chemokines (Rudolph et al. 2006, Janeway et al. 2001, 
Broere et al. 2011).  
This activation process of the T cell informs the DC whether to assume 
an inflammatory or regulatory phenotype hereafter, alerts other immune cells 
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to the antigens presence, and polarizes T cells, which can result in activation 
and expansion of T effector cells and B cells or T regulatory cells (Tregs) 
(Broere et al. 2011, Janeway et al, 2001, Mennechet et al. 2006). Overall, this 
DC-T cell interaction creates positive and negative feedback loops filled with 
information on how to proceed with the antigen-specific immune response 
(Broere et al. 2011, Janeway et al. 2001, Steinman et al. 2007).  
 
 
 
 
 
 
 
 
This fluid and dynamic interaction between the DC’s MHC II-peptide 
complex and the T cell’s TCR is the basis for the immunological synapse (IS) 
(Figure 4) (Griffiths et al. 2010, Bromley et al. 2001, Viola et al. 2010, 
Steinman et al. 2007, Huppa et al. 2003). The IS encompasses the 
environment generated by the coupling of DCs and T cells, such as it relates 
to the membrane structure, T cell polarity, signaling compartmentalization, the 
Figure 4. A mature Immunological Synapse (IS). The IS 
represents the events leading up to and the formation of the 
nanometer scale gap interaction between APCs and T cells, as 
well as the subsequent T cell polarity and signaling pathways 
activated by this synapse formation. 
Image from Huppa et al. 2003.  
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antigen-presenting cell, and quality of antigen presented (Bromley et al. 2001, 
Viola et al. 2010, Huppa et al. 2003, Grakoui et al.1999). This interaction 
results in T cell activation and the initiation of an antigen-specific T cell 
mediated adaptive immune response (Janeway et.al 2001, Male et al. 2006, 
Broere et al. 2011, Bromley et al. 2001, Huppa et al. 2003). Thus, antigen 
trafficked to the DEC-205 receptor can lead to the generation of either a T cell 
effector or regulatory antigen-specific immune response (Steinman et al. 2007, 
Tacken et al. 2007, Bonifaz et al. 2002). 
  
Adaptive Immunity 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5. Naïve T cell differentiation. After a naïve T cell recognizes 
and binds to a peptide-MHC complex, a cascade of events occurs 
intracellularly and extracellularly that allows the naïve T cell to 
undergo differentiation. Image from O’Shea and Paul, 2010.  
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Adaptive immunity refers to the immune responses generated to a 
specific peptide-MHC complex that are then recognized by antigen-specific T 
cells (Steinman et al. 2006, Janeway et al. 2001). Adaptive immunity is slow 
acting, but it is more specific and targeted against a particular pathogen 
(Janeway et al. 2001, Steinman et al. 2007). From adaptive immunity, two 
types of IS induced immune responses are possible: A tolerogenic immune 
response or an effector immune response (Janeway et al. 2001, Steinman et 
al. 2007).  
Generally, an effector immune response is generated after T cell 
recognition and activation to peptides presented in context of MHC molecules 
and co-stimulatory signals provided by APCs (Figure 5) (Steinman et al. 2007, 
Janeway et al. 2001). Signal 1 consists on the foreign peptide presented by 
the MHC II molecule and signal 2 is provided by the co-stimulatory proteins 
produced, up-regulated, or secreted during the IS interaction, such as CD28, 
CD80, and CD86 (Janeway et al. 2001, Rudolph et al. 2006, Bromley et al. 
2001, Viola et al. 2011). An effector immune response would result in a robust 
pro-inflammatory immune response characteristic of pro-inflammatory 
cytokines, such as IL-1, TNFα, IFN-y, IL-2, IL-4, or IL-12 (Hart, 1997, Dinarello 
et al. 201, Lipscomb et al. 2002, Wilson et al. 2003, Desombere et al. 2004). 
 A tolerogenic immune response is very similar in process to the effector 
immune response as it too is controlled directly or indirectly by the up-
regulated and secreted proteins resulting from a chain of cellular interactions 
initiated by the presentation of bound peptide (Barbosa et al. 2007). However, 
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there are a few key differences: The bound peptide is from “self-protein” and 
there are limited numbers of cytokines and cell surface receptors present 
(Janeway et al. 2001). Those key differences, overall, result in a regulatory 
immune response with either the interacting T cell or DC secreting regulatory 
cytokines such as TGF-β or IL-10 (Josefowicz et al. 2012). T helper cells will 
become activated via the cytokine signaling of TGF-β or IL-10 and differentiate 
into Tregs (Male et al. 2006, Josefowicz et al. 2012).  
 
Regulatory T cells 
 Regulatory T cells (Tregs) are the mediators of the immune system. 
Tregs, after activation, secrete regulatory cytokines that inhibit effector T cell 
responses. They are featured prominently in autoimmune diseases, 
inflammatory disorders, peripheral tolerance, and immune homeostasis 
(Josefowicz et al. 2012, Lio et al. 2010, Lee et al. 2014, Burchill et al. 2008). 
Tregs are one way for the immune system to protect itself against reacting to 
“self-protein”, as well as have the capacity to minimize the effects of 
inflammation and damage induced by pathogens (Josefowicz et al. 2012, Male 
et al. 2006, Janeway et al. 2001, Lio et al. 2008, Burchill et al. 2008). Tregs 
are characterized as suppressive immune cells whose phenotypes are 
CD4+CD25+FoxP3+. They require the presence of CD28, IL-2, and to a lesser 
extent IL-7 and IL-15, in order to become activated and fully differentiated 
(Josefowicz et al. 2012, De Groot et al. 2008, Lio et al. 2008, Burchill et al. 
2008). FoxP3 is a forkhead family transcription factor that has come to be 
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associated with Tregs, and, though not a definitive marker, its presence still 
supports a dedicated function in Treg cell differentiation, as was reported in 
FoxP3 reporter mice cells CD4+CD25-FoxP3+ (Josefowicz et al. 2012, Ohkura 
et al. 2012).  
 
Induction of a Tolerogenic Immune Response 
As reported in past studies, OVA antigen delivered by the 
αDEC205:OVA antibody to the DEC-205 receptor is internalized and 
processed by DCs (Bonifaz et al. 2002). Processing of the protein complex 
generates peptide fragments that are then loaded, if possible, onto the MHC II 
molecule for presentation to T cells (Bonifaz et al. 2002, Tacken et al. 2007, 
Steinman et al. 2006). Normally, delivery of antigen with this targeted vehicle 
induces a tolerogenic immune response when no maturation factor is used 
(Bonifaz et al. 2002, Steinman et al. 2006, Tacken et al. 2007, Uto et al. 2013).  
 
 
 
 
 
 
 
Figure 6. The Tregitope-effect concept. This figure depicts the concept 
behind the induction of a tolerogenic immune response that is observed 
after the αDEC-205:OVA antibody, without a maturation factor, is used 
during immunizations. Provided by Weber et al., 2008. 
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Presentation of tolerogenic signals or natural T regulatory cell epitopes 
(Tregitopes) is hypothesized to induce the tolerogenic immune response when 
the αDEC205:OVA antibody is used in immunizations (De Groot et al. 2008, 
De Groot et al. 2013). Derived from IgG molecules, Tregitopes are potentially 
found in both the F’ab (framework) and Fc regions of an antibody (De Groot et 
al. 2008, Cousens et al. 2013). Tregitopes are highly conserved in IgG 
molecules and considered highly promiscuous due to binding to various HLA 
alleles (De Groot et al. 2008, Cousens et al. 2013). Due to the “foreign” (not 
seen in thymic development) somatic hypermutations at the variable region’s 
antigen-binding site in IgG molecules, it is hypothesized that highly conserved 
sequences (Tregitopes) were retained throughout evolution for self-protein 
(IgG molecules) to escape immune system recognition (De Groot et al. 2013, 
Janeway et al. 2001, Livesay et al. 2004).  
Published findings show an induction of tolerance owing to Treg 
expansion (CD4+CD25+FOXP3+) when Tregitope sequences are co-cultured 
with peripheral blood mononuclear cells (PBMCs) (De Groot et al. 2013). 
These studies were eventually replicated by Zambidis and Scott (1996) and 
found that an IgG’s heavy chain fused to antigen induced tolerance as well, 
where current human Tregitopes (167 and 289) are found in the constant 
heavy chain FC region (De Groot et al. 2008). Thus, Tregitopes, found within 
the αDEC-205 antibody’s sequence, are thought, once presented by MHC II 
molecules, to activate Tregs, upregulate Treg associated cytokines and 
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chemokines, and subsequently induce an antigen-specific regulatory immune 
response (De Groot et al. 2008, Singh et al. 2012, Cousens et al. 2013). 
 
Proposed Objective 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Adjuvants are believed to be required for the αDEC205:OVA antibody’s 
targeted antigen delivery due to Tregitope presence in the IgG delivery vehicle 
(De Groot et al. 2008). Adjuvants are used to induce a robust and sustained, 
Figure 7. A 3-D model of the αDEC-205 antibody with the targeted 
Tregitopes highlighted in blue and red. Tregitopes or natural T 
regulatory cell epitopes are potentially highly conserved sequences 
found in all IgG molecules. When Tregitopes are presented they are 
believed to induce CD4+CD25+FoxP3+ regulatory T cells. Two 
Tregitope sequences, HC54 and VH77, are highlighted in red and 
blue, respectively. HC54 sequence (red) is found in the constant 
heavy chain region and the VH77 sequence (blue) is located in the 
variable heavy chain region. Model provided by Dr. Yoonjoo Choi 
and Dr. Chris Bailey-Kellogg (Dartmouth).   
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strong T cell mediated immune response to the specific antigen fused to the 
antibody (Steinman et al. 2000, Hill et al. 2007). Therefore, selected Tregitope 
sequences within the αDEC-205:OVA antibody are modified to diminish 
tolerogenicity, which will inhibit Treg activation, and promote immunogenicity 
to less immunogenic peptides, such as the vaccine test antigen, ovalbumin. 
This approach removes the need for non-specific activation of the immune 
system (De Groot et al. 2008, Moise et al. 2012).  
The proposed objective is to compare the variant αDEC-205:OVA 
immunization conditions’ immunized splenocytes’ responses to the non-
modified αDEC-205:OVA-ORG immunization condition’s immunized 
splenocytes’ responses. Splenocyte responses are observed in two 
immunogenicity assays to determine if a greater pro-inflammatory immune 
response, characteristic of T cell proliferation and pro-inflammatory cytokine 
signaling, is observed when immunizing mice with the Tregitope modified 
antibody sequences. This will help to uncover whether Tregitopes are the 
cause for tolerogenic effects when antigen is administered in the absence of 
an adjuvant.  
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CHAPTER 3 
 
MATERIALS AND METHODS 
Mice 
HLA-DRB1*0401 (DR4) mice are a transgenic humanized HLA mouse 
model derived from a C57BL/6 background that are used to test vaccine 
efficacy and T cell responses specific to the DR4 allele (Ito et al.1996). The 
DR4 mice are brought in from Taconic and cared for in-house in the bio-safety 
level 2 (BSL-2) trailer located at Peckham Farm on the University of Rhode 
Island’s Kingston campus (Ito et al.1996, Grusby et al.1991). The mice 
founders of this transgenic line were initially crossed with MHC II deficient 
mice (Genpharm C2d line), which has the I-A beta gene inactivated and the 
unexpressed I-E alpha allele found in the C57BL/6 haplotype (Ito et al. 1996, 
Grusby et al. 1991). Mice contain hybrid MHC II molecules that contain the 
peptide binding domain specific to the HLA-DRA and HLA-DRB1*0401 allele  
(Ito et al. 1996, Grusby et al.1991).  
 
Antibodies 
The αDEC-205 antibody recombinant expression constructs were 
obtained from Dr. Ralph Steinman (The Rockerfeller University). Aldevron 
produced the high titers (1 mg/mL) of the original wild type αDEC-205 antibody  
(ORG) and modified antibodies αDEC-205:OVA-CH54-MOD1, αDEC-
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205:OVA-VH77-MOD1, αDEC-205:OVA-VH77-MOD2 (MODs). αDEC-205 is a 
chimeric, monoclonal, rat-α-mouse antibody that is transfected and expressed 
in the Chinese Hamster Ovary (CHO-S) cells mammalian expression system 
(Invitrogen-Life Technologies R800-07). The ovalbumin whole protein (45 kD), 
a major component of chicken egg white, was recombinantly fused via linker 
protein sequence to the C-terminus of the αDEC-205 heavy chain (Yasushi).  
The staining antibodies used in the imunogenicity assays are 
purchased from eBioscience, BDBiosciences, or Life Technologies 
(Affymatrix) and can be viewed in the table below (Table 1-2). The fluorescent 
cell-staining dye, CFSE (Carboxyfluorescein succinymidal ester) was 
purchased from Life Technologies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody/Stain Manufacturer Clone 
αms-IgG-FitC eBiosciences GK5.1 
αCD11c-PE-Cy7 eBiosciences 145-2C11 
Table 2. The T cell proliferation assay antibody staining 
panel.   
Antibody/Stain Manufacturer Clone 
αCD4-BV 421 BD Biosciences GK5.1 
αCD8a-APC BD Biosciences 53-6.7 
αCD3e-PE BD Biosciences 145-2C11 
CFSE Life Technologies n/a 
 
Table 1. The JAWS II DC binding assay antibody staining 
panel. 
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JAWS II Dendritic Cells  
A bone marrow derived-C57BL/6 background dendritic cell line, JAWS 
II DCs (ATCC-CRL-11904), are passaged once weekly at a 2:1 (cells: culture 
media) ratio utilizing αMEM culture media supplemented with deoxy and ribo-
nucleosides, 5% L-glutamine 100x (Invitrogen 25030-156), 5% Sodium-
pyruvate (Hyclone-SH3023901), 10% Fetal Bovine Serum (Invitrogen 10100-
147), 5% Penicillin/Streptomycin (Invitrogen 15140-122), and Granulocyte 
Macrophage-Colony Stimulating Factor-Recombinant Mouse (R&D systems: 
415ML010) in T-75 flasks, as per manufacturer’s (ATCC) instructions (ATCC-
CRL-11904).   
Immunoinformatics Analyses: The EpiMatrix System 
EpiMatrix 
 The αDEC-205 sequence was computationally screened for putative 
HLA-Class II restricted conserved T cell epitopes with the use of an in silico 
tool, EpiMatrix (Table 1). EpiMatrix identifies which 9 amino acid frames are 
predicted to bind to specific HLA alleles and are highly conserved in existing 
databases of IgG sequences (De Groot et al. 2013, De Groot et al. 2014). 
Protein antigens are parsed into overlapping 9-mer frames. Each 9-mer frame 
overlaps the last frame by eight amino acids. 9-mer frames are scored against 
a panel of 8 class II “supertype” alleles that comprise at least 90% of the 
world’s human HLA genetic makeup to determine the epitope’s binding 
potential to each of the 8 common class II alleles: DRB1*0101, *0301, *0401, 
*0701, *0801, *1101, *1301, and *1501 (De Groot et al. 2008, Cousens et al. 
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2013, Singh et al. 2012). The EpiMatrix algorithm compares the amino acid 
sequence of each 9-mer frame to the coefficients contained in the matrix, 
which produces a raw score for each frame. The raw score is then converted 
to a normalized z-scale. The EpiMatrix z-scale provides z-scores, allowing for 
comparison of potential epitopes to multiple class II HLA alleles (De Groot et 
al. 2008, Singh et al. 2012). Peptides scoring ≥ 1.64 (top 5th percentile) on the 
EpiMatrix “Z”-scale are predicted MHC II ligands. The higher the EpiMatrix “Z” 
score, the more likely the peptide sequence is an MHC ligand and a T cell 
epitope (De Groot et al. 2008). The EpiMatrix Cluster analyses reported 
predictions for each 9mer frame sequence with top 10% z-scores (hits) or 
greater. The relevant z-scores can be read as follows, top 10% hits are 
highlighted in the lightest blue, the top 5% hits in a bluish-grey, and the top 1% 
hits are highlighted in dark blue (Table 5). The top 1% and 5% hits reported in 
all the EpiMatrix Reports have z-scores ≥ 2.30 and scores between 1.64-2.29, 
respectively (Table 5).  
ClustiMer 
 ClustiMer is a ancillary algorithm used with EpiMatrix analyses and 
identifies areas densely laden with putative T cell epitope clusters with high-
scoring EpiMatrix z-scores throughout the entire antibody sequence 
(Sintechenko et al. 2010). More specifically, ClustiMer maps the EpiMatrix 
motif matches along the length of a protein and calculates the density of motifs 
against the panel of eight HLA alleles (De Groot et al. 2008, Sintechenko et al. 
2010). T cell epitope clusters with ClustiMer scores ≥ 10 indicate a significant 
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potential for immunogenicity for a given epitope sequence. Clusters usually 
range between 9-25 amino acids in length and can have 4-40 binding motifs 
(De Groot et al. 2008). All high scoring putative T-cell epitope clusters 
ultimately are compared to human IgG sequences and only cluster sequences 
showing homology to human IgG, potentially regulatory sequences, were 
selected for targeted modification, to reduce binding potential to the HLA-
DRB1*0401 allele (De Groot et al. 2008, Caspi, 2008, Parker et al. 2010).  
OptiMatrix 
OptiMatrix, the final algorithm, identifies amino acids contributing the 
most to the T cell epitope’s HLA binding affinity to a specific allele and targets 
the amino acids for select modifications, to reduce binding potential (De Groot 
et al. 2008). Each epitope sequence modification is dependent on the 
individual amino acid’s binding affinity to the MHC II molecule and the 
predicted effect it will have on the HLA binding affinity (De Groot et al. 2008). 
Only amino acid substitutions that resulted in the reduction of the epitope 
sequence’s EpiMatrix z-score were chosen for potential incorporation into the 
full-length αDEC-205:OVA-ORG antibody. A reduction in the predicted 
EpiMatrix z-score correlated to that particular epitope sequence’s decrease in 
predicted binding affinity for a given HLA-allele (Moise et al. 2012, De Groot et 
al. 2008).  Generally, amino acids located within the MHC II anchoring peptide 
positions are modified first, since those amino acids are key to that peptide’s 
affinity to the MHC molecule (De Groot et al. 2008). Normally, both alanine or 
glycine are chosen as amino acid replacements because they are least likely 
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to interact with the surrounding peptides within the MHC II molecule’s binding 
groove and provide less steric hindrance (De Groot et al. 2008). Alanine 
substitutions have shown in previous work by Warmerdam et al. to result in 
de-immunization of the epitope and reduce or eliminate a subsequent T cell 
response (Schönbach et al. 2008).  
Site Directed Mutagenesis 
The suggested modifications were incorporated into the full-length 
αDEC-205:OVA sequence by Site Directed Mutagenesis to produce an array 
of αDEC-205 antibody variants via Stratagene’sQuikChange® XL II Site-
Directed Mutagenesis Kit, per manufacturer’s instructions. The procedure 
enables site-specific mutations within double-stranded plasmids and 
eliminates the need for specialized vectors and unique restriction sites. Normal 
thermo-cycling procedures involving denaturation of plasmid at 95°C for 1 
cycle, annealing of the mutagenic primers complementary to opposite strands 
of the plasmid, and subsequent elongation of the mutagenic primers for 18 
cycles, resulting in the synthesis of mutant strands (Quik Change XL II-
200522). Left over hemi-methylated and methylated parental DNA strands 
were removed by Dpn I endonuclease digest. Resulting nicked-mutant strands 
were then transformed into XL10 gold bacterial cells where ligation and 
subsequent transformation into bacterial cells occur (Quik Change XL II- 
200522). Newly transformed XL 10 gold bacterial cells containing the mutant 
strands were streaked on Agarose gel plates containing ampicillin. 
Immediately following, streaked plates were placed in a 37ºC incubator for 
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overnight cell growth. Only bacterial cell colonies that had properly taken in the 
plasmid and potentially the mutagenic strands would have been able to grow 
due to antibiotic resistant genes present within the plasmid. Thus, colonies 
were chosen the following morning for plasmid purification purposes. The very 
same day, plasmid DNA was isolated from the top 10 cells via lysing 
techniques and purified using Qiagen-mini prep techniques (QIAGEN-Kit Cat. 
No. 27104). The purified plasmids containing the select amino acid 
modifications to targeted potential Tregitope sequences were sent for 
confirmatory sequencing and high production yields (1 mg/mL) of low 
endotoxin plasmid to Aldevron.   
 
Transfection of CHO-S cells 
Chinese Hamster Ovary-S cells (CHO-S) (R800-07) were passaged 
day prior to transfection, at 5 x106 cell/mL in FreestyleTM CHO Expression 
Media (12651-014) as per manufacturer’s instructions (Invitrogen-Life 
Technologies-K9000-20). Flasks were placed in an orbital shaker platform 
(120-135 rpm) at 37ºC, 8% CO2. On the day of transfection the CHO-S cell 
density must range between 1.2-1.5 x106 cell/mL. Cells were counted via 
Cellometer and the live cell viability is recorded. A 95% cell viability or greater 
is also required to ensure high transfection results. 30 million cells were taken 
from the repository culture flask and were loaded into a new 125 mL culture 
flask that is placed into a 37ºC incubator for acclimation purposes.  
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Immediately following, 37.5 ug of each respective plasmid DNA is 
aliquoted into FACS test tubes and mixed with 0.6mL/test tube of OptiProTM 
SFM (123-9-050). Concurrently, in separate tubes, the FreestyleTM MAX 
Transfection Reagent (16447-100) is diluted with up to 0.6mL/test tube of 
OptiProTM SFM. Plasmid DNA preparations were mixed with their respective 
transfection reagent-OptiPro solutions, yielding mixed transfection reagent-
DNA solutions. Mixed DNA-transfection solutions incubated for 10 minutes 
(min.) at room temperature, enabling formation of plasmid DNA-reagent 
complexes. The DNA-reagent complex solutions were added to the respective 
previously acclimated 125 mL culture flasks. Culture flasks were then loaded 
into the orbital shaker platform within the 37ºC, 8% CO2 incubator for a 
maximum of 7 days (Invitrogen). During the 7-day time frame, cell viability is 
checked everyday to determine the optimal “harvest” day. Generally, cells are 
harvested on the 7th day due to 60-80% cell viability throughout the entire 
transfection period. Once the cells were harvested, the cell pellet was 
separated from the supernatant and discarded. Supernatants are stored at -
20ºC until protein purification.  
 
Protein Purification 
 Supernatants were processed one of two ways: By normal flow filter 
concentration prior to column purification or just column purification. At times, 
if supernatant volumes surpassed a certain volume, the flow filter 
concentration is used to concentrate the supernatants prior to loading on the 
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AKTA Avant liquid chromatography system. A collection of supernatants, 300 
mL volume maximum, were thawed and loaded into the protein concentrator. 
A specific size exclusion membrane is used that only allows protein sizes up to 
the molecular weight of the αDEC-205:OVA-ORG antibody to pass. The 
concentrated supernatant was then collected into a secondary stationed 50 
mL test tube for column purification on the AKTA Avant. All larger extraneous 
protein is prevented from passing and maintained in the protein concentrator.  
 If that step was not warranted and was by passed, then supernatants 
were purified using the AKTA Avant liquid chromatography system as per 
manufacturer’s instructions (GE Healthcare Life Sciences). The supernatant 
was streamed over a protein G column that contains bound Fc-receptors that 
bind specifically to the protein of interest. Immediately after, a wash buffer was 
ran over the protein G column to ensure the extraneous protein was washed 
off the column and out of the machine. A second buffer containing competing 
ligands was ran over the protein G column and the ligands bind to the Fc 
receptors, outcompeting the protein of interest. The bound protein was eluted 
off the column and into waiting micro-centrifuge tubes. A sudden spike in 
protein concentration, represented as peaks on the AKTA Avant’s display 
screen, alert to the presence of eluted protein in micro-centrifuge test tubes.  
Fraction samples collected at various time points during the purification 
process, such as prior to supernatant loading into the AKTA Avant, 
supernatant (flow through) run-off once ran over the protein G column, wash 
cycle run-off, and finally a sample of from the final purified eluate (Figure 8).  
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These fraction samples were ran on a sodium dodecyl sulfate (SDS) 
polyacrylamide (PAGE) gel and western blot to confirm purity of protein, 
molecular weight of protein, and if any protein was lost throughout the 
procedure. After protein purification confirmation, the newly purified protein’s 
concentration was analyzed via Nano Drop. The protein was aliquoted into 
working stock solutions and stored at 4ºC until further use.  
 
Dendritic Cell Binding Assay 
 DC binding assays were performed to determine if the variant αDEC-
205:OVA antibodies, after modification, were capable of targeting and binding 
to the DEC-205 receptor found on DCs after modification. JAWS II DCs were 
aliquoted into FACS test tubes at 1 x 106/mL. Instantly, 5 ug/mL of purified wild 
type and variant αDEC-205 antibodies were added to respective FACs test 
tubes. The DC-antibody mixtures were cultured for 30 min. at room 
temperature; this allows time for the antibodies to target the DEC-205 
endocytic receptor. After the 30 min. incubation, DCs were washed twice 
more. Afterwards, the FACs test tubes containing the wild type and variant 
αDEC-205:OVA antibodies were stained with a rat-α-mouse IgG-PE antibody 
for 1hr at 4ºC. This antibody only detects the αDEC-205:OVA antibody 
attached to the DEC-205 receptor on the DC surface. Any αDEC-205:OVA 
antibody not bound to the DEC-205 receptor was washed away after the 
staining incubation in subsequent washes. DCs were then immediately 
analyzed on the BD LSRII Flow Cytometer. The rat-α-mouse IgG-PE staining 
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antibody allows for fluorescence intensity quantitation based on antibody 
targeting capacity to the DEC205 receptor.  
   
Immunization and Splenocyte Isolation Procedure 
 Immunizations to the 16 HLA-DR4 mice were performed using a 27’’ 
gauge needle for subcutaneous injections to the left hind flank. Immunizations 
occur at the BSL-2 trailer at Peckham Farm on the University of Rhode 
Island’s Kingston Campus. Immunizations and splenocyte culturing 
procedures were followed according to a previously described protocol 
(Bonifaz et al. 2004) with minor procedural adjustments.  
 16 HLA-DRB1*0401 mice are immunized on Day 0 and after a 7-day 
time period mice were anesthetized with isoflurane (inhalant) via an oxygen 
chamber and then euthanized with Ketamine (100µl/mouse). After euthanasia, 
spleens were immediately harvested, put on ice, and transported back to 
URI’s Feinstein Providence Campus (Bonifaz et al. 2004). Once back at the 
lab, the splenocyte isolation procedure begins.  
Splenocytes were isolated from their tissue matrix via maceration of 
spleens over a 40µm nylon mesh filter that sits atop a 50 mL test tube. This is 
performed for each respective immunization condition. Resulting splenocytes 
are not pooled together and remain in their respective 50 mL collection test 
tube. Afterwards, the filters atop of the 50 mL collection test tube were washed 
with 10 mL RPMI-1640 culture media to displace residual splenocytes. A 
Cellometer is then used to count the number of living splenocytes there are 
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per milliliter of solution. Trypan blue, a viability dye exclusion method is used 
to identify live and dead cells (Tran et al. 2011). Trypan blue was added to an 
aliquot of cells and then loaded onto a counting chamber specific to the 
Cellometer, which then determines the live cell concentration and viability of 
the splenocyte samples. Splenocytes were separated according to number 
requirements for each immunogenicity assay. Both memory response 
immunogenicity assays, a T cell proliferation assay and a Murine (Mu)-
Interferon-gamma (IFN-γ) enzyme-linked immunospot assay (ELISpot), were 
used to detect splenocyte pro-inflammatory tendencies observed from antigen 
re-stimulation (Desombere et al. 2004, Desombere et al. 2005).  
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Table 3. HLA-DRB1*0401 mice immunization 
conditions. 
Group ID Mouse ID Immunization 
Conditions 
A 
A1 
Negative CTL (PBS) 
A2 
B 
B1 Antibody CTL 
(αDEC:OVA-ORG) B2 
C 
C1 
αDEC:OVA + CD40 
C2 
D 
D1 
αISO:OVA + CD40 
D2 
E 
E1 
Adjuvant CTL (CD40) 
E2 
F 
F1 αDEC:OVA-HC54-MOD1 
(MUT1) F2 
G 
G1 αDEC:OVA_VH77-MOD1 
(MUT2) G2 
H 
H1 αDEC:OVA_VH77-MOD2 
(MUT3) H2 
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Ex vivo T cell proliferation assay  
 Splenocytes were resuspended in prewarmed PBS/0.1% Fetal Bovine 
Serum (FBS) at a final concentration of 1 x 107 cells/mL. CFSE labeling (1µM) 
was performed per manufacturer’s instructions (Life Technologies) prior to 
culture. Splenocyte containing FACs test tubes receive 1µL of the 1µM CFSE 
solution and were incubated for 10 min. at 37ºC. With the addition of ice-cold 
culture media at five times the volume, the CFSE staining process was 
quenched. Immediately following, splenocytes were incubated for 5 min. in an 
ice bath. After splenocytes are washed three times, they were plated in a 48-
well flat-bottomed plate at 1 x 106 cells/0.5 mL. Prior to 72hr 37ºC incubation, 
splenocytes were re-stimulated with ovalbumin at 500µg/mL. Ovalbumin 
antigen re-stimulation is done to identify if splenocytes can recall antigen-
specific T cell response due to initial immunizations with ovalbumin (Bonifaz et 
al. 2004). 
 Following the 72hr incubation, splenocytes were harvested and stained 
with fluorophore-conjugated antibodies (Table 2) for 1hr at 4ºC. After the 1hr 
incubation, excess staining antibody was removed with splenocyte washing. 
Splenocytes were then analyzed for T cell proliferation on the BD LSRII Flow 
Cytometer. For this particular experiment, CD3+CD4+ T helper cells and 
CD3+CD8+ Cytotoxic T cells were identified amongst the splenic population 
and measured for percent T cell proliferation. Of particular interest is the 
percent T cell proliferative responses of the αDEC-205:OVA-ORG antibody 
immunized splenocyte responses to ovalbumin re-stimulation in comparison to 
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the proliferative responses of the variant αDEC-205:OVA antibody immunized 
splenocytes. 
 
Ex vivo ELISpot assay 
The capture and detection antibodies were supplied by MABTECH and 
the ELISpot assay protocol was followed per manufacturer’s kit instructions 
(Ngai et al. 2007). Splenocytes were loaded into Mu-IFN-γ 96-well round-
bottomed plates pre-coated with an IFN-γ binding capture antibody. Plates 
were then washed four times with 1x Phosphate Buffer Saline (PBS) and 
loaded with 150 uL RPMI-1640 culture media for 30 min. at room temperature. 
Following this, splenocytes were then plated at 250,000cells/well. All 
stimulations were performed in triplicate; the negative controls were 
represented with 6 wells each comprising splenocytes and media alone. 
Afterwards, each well was re-stimulated, if necessary according to the 
experimental plan. Antigen stimulations included OVA class I (257-264) and OVA 
class II (323-339) peptides (10 µg/mL) as per the previously described protocol by 
Bonifaz et al. (2004) (Table 4). The Class I and II OVA peptides were 
predicted to bind to the DR4 allele and have shown to be capable of detecting 
and inducing activation and proliferation of CD8+ Cytotoxic T cells and CD4+ T 
helper cells, respectively (Bonifaz et al. 2004, Sun et al. 2010). Concanavalin 
A (CON A) was added to the positive control wells only (2 µg/mL). CON A is 
normally used as a positive control treatment condition because it readily 
triggers T cell activation and proliferation (Palacios, 1982). Plates were then 
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placed in a 37ºC incubator for 48 hr.  
After the 48hr incubation, plates were washed five times and IFN-γ 
production was detected according to the MABTECH development protocol. 
The biotinylated-detection antibody (R4-6A2-biotin) was then diluted to 1ug/mL 
in PBS containing 0.5% FBS and 100µL was added to each well. Following 
this step, plates were incubated for 2hr at room temperature. After incubation, 
plates were re-washed and 100 µL Streptavidin-Horseradish Peroxidase 
(HRP) conjugate (diluted 1:1000) was added to each well. Plates were then 
incubated at room temperature for 1hr. Following incubation, to visually 
observe if IFN-γ secretion occurred due to antigen re-stimulation, plates were 
washed and then loaded with 100µL TMB substrate per well. The plates were 
immediately left to develop for a maximum of 10 min. at room temperature, 
until distinct blue spots emerged. The colorimetric TMB substrate forms an 
insoluble precipitate when catalyzed by the Streptavidin-HRP enzyme and 
acts as a visible representation of a single activated cell secreting the IFN-γ 
cytokine (MABTECH). Each plate’s color development was stopped after 
extensive plate rinsing with tap water. Plates were left to dry overnight and 
inspected for spots the following day, utilizing the ELISpot Reader (Cellular 
Technologies Limited, Cleveland, OH).  
In general, a positive T-cell response was defined by a significantly 
elevated spot count in antigen-stimulated wells over the non-stimulated media 
only-control (negative-control), usually, 50 spot forming units above 
background was considered a positive response (Dittrich et al. 2012). The 
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data generated by the ELISpot Counter was then compiled into an excel 
spreadsheet. Each triplicate’s spot data, not including the negative controls, 
was added together and then averaged, resulting in one value representative 
of the immunization condition’s positive control and antigen stimulated 
samples. As for the negative controls, all 6 wells per respective immunization 
condition were added together and then averaged. The resulting negative 
control values represent the background “noise” of the assay. Each 
immunization condition’s negative control values were then subtracted from 
their respective antigen stimulated averaged sample values. The newly 
generated averaged data was then normalized to 1 million cells. The resulting 
spot count data now represents an actual IFN-γ response due to antigenic 
peptide re-stimulation.  
 
 
 
 
 
 
 
 
Flow Cytometry 
The BD LSRII Flow Cytometer identifies and functionally characterizes 
various cellular population subsets (BDBiosciences). Prior to all experiments, 
Table 4. OVA Class I and Class II peptide sequences. 
Specific peptide sequences were found within the whole 
protein, Ovalbumin, which was used in the Mu-ELISpot 
IFN-γ assay as a method of antigen re-stimulation.   
OVA Peptide ID Sequence 
Class I (257-264) SIINFEKL 
Class II (323-339) ISQAVHAAHAEINEAGR 
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compensation must be performed to inform the machine of each antibody 
stain’s fluorophore fluorescence intensity (FI) and to confirm each 
fluorophore’s FI matches perfectly with the specified cell marker-antibody stain 
used. Compensation is also necessary to perform when multiple fluorophores 
are used per assay and per cell because it also addresses the issue of 
spillover, which is the physical overlap of emission spectra (BD Biosciences). 
Filters are in place in the machine to try and prevent as much spillover of 
fluorescence spectra as possible, however, most fluorophores emit over a 
broad range of wavelength so a compensation process is required to subtract 
the fluorescence spectral spillover from other channels (BD Bioscience). Data, 
for all samples, was acquired on the same day using the BD LSRII Flow 
Cytometer to assure consistency among samples. Once sample acquisition 
was complete, samples are analyzed with BD’s FacsDiva Software V8.0 and 
Tree Star’s FlowJo Analysis Software V7.6.5. 
 
Statistical Analyses 
 Data generated from both ex vivo memory immune response assays is 
taken and compiled into an excel spreadsheet. Analyses are performed per 
experiment using the Mann-Whitney U test in the GraphPad Prism 6 software, 
a non-parametric t-test that measures for the significant difference between 
two groups of independent samples (Doerge et al. 2009). This test is normally 
used when the data set does not meet the requirements for a parametric t-test, 
such as the data set is not normally distributed (Doerge et al. 2009). Each 
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sample condition’s data set was tested for normal distribution using the 
Shapiro-Wilk frequency distribution test. All data sets were shown to not have 
normal distribution (not shown). Both data sets for the two conditions that were 
compared were compiled together and then ranked from lowest to highest. If 
identical values were present within the data set, each of the values respective 
ranks are added together and then averaged to break the tie (Doerge et al. 
2009). From now on, only the ranking values are used rather than the 
measured data value. Therefore, the ranks are separated back into their 
respective sample conditions and the sum is taken. Each sample condition’s 
rank total is then used to observe the differences between the two conditions.  
Generally, if there is a systematic difference, the sample condition receiving 
the significantly greater immune response will tend to have the higher-ranking 
values, while the other sample condition will tend towards the lowering ranking 
values (Doerge et al. 2009). However, if both sample conditions generate a 
similar immune response then both high and low ranking values are distributed 
fairly amongst the two sample conditions, and both rank totals will be fairly 
similar (Doerge et al. 2009).  
One of the statistics generated from the ranked data set is a p-value. 
The p-value is a probability and measures the strength of evidence against the 
null hypothesis. The assumption being the null hypothesis is true (Stills, 2005). 
Thus, it measures the likelihood of significance and whether the difference 
observed between the two data sets likely is to occur by random chance 
(Stills, 2005). All Mann-Whitney-U statistical analyses performed for these 
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assays are one-tailed with a 95% confidence interval, therefore, the p-value 
significance level threshold is set at 0.05. Any p-value score that is lower than 
the 0.05 significance level threshold is considered significant and the null 
hypothesis can be rejected. Generally, the lower the p-value score, the more 
significant and the greater the difference observed between two sample 
conditions (Stills, 2005). 
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CHAPTER 4 
 
FINDINGS 
In silico Analyses 
 In order to first create a de-tolerized antibody, tolerogenic signals must 
be located within the αDEC-205 antibody’s sequence. Specific amino acids 
within the Tregitope sequence, at key positions, were selected for 
modification. The aim was to perform the least amount of substitutions as 
possible to minimize the likelihood of disruption to structure and function of the 
antibody sequences, as well as, reduce binding potential to the respective 
HLA allele (Moise et al. 2012). Therefore, the entire EpiMatrix suite of tools 
were used to identify T cell epitopes, potentially regulatory in nature, based on 
criterion defined in the epitope-mapping algorithms and suggest and substitute 
in key amino acid replacements in order to reduce the binding potential of the 
tolerogenic signals to the HLA allele  (De Groot et al. 2008).  
EpiMatrix Cluster report analyses showed EpiMatrix z-scores for each 
of the 8 alleles; however, only the DR4 allele was of interest due to future in 
vivo immunizations taking place in HLA-DR4 mice (Tables 5-9). In total, only 
two out of the six Tregitope sequences within the αDEC-205 antibody’s 
sequence were targeted for modification (VH77 & HC54) based on previous 
research performed by De Groot et al. 2008 indicating that VH77 
(unpublished) and HC54 Tregitope sequences are the most immunogenic out 
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of the six Tregitopes. These two Tregitope sequences comprise the most 
potential for driving this tolerogenic immune response based on prior research 
showing ex vivo expansion of CD4+CD25+FoxP3+ T cells when Tregitopes are 
used as stimulation conditions for PBMCs (De Groot et al 2008, De Groot et 
al. 2013, Cousens et al. 2013). Tregitope sequences HC54 and VH77 were 
defined as 22 and 23 amino acid length sequences, respectively (Table 10). 
Both HC54 and VH77 Tregitope sequences, with respect to the HLA-
DR4 allele, contain four hits in total, with three of the four hits in at least the 
top 5th percentile for peptides likely to bind to the DR4 allele for each 
sequence (Tables 5,7). This suggests there are three potentially regulatory 
sequence frames within both Tregitope sequences (HC54 and VH77) that are 
predicted to bind to the HLA-DR4 allele. The EpiMatrix Cluster reports showed 
Tregitope sequences, αDEC-205:OVA-HC54-ORG and αDEC-205:OVA-
VH77-ORG, have 2.5 Epibars and 4 Epibars when compared against the 
panel of 8 class II alleles, respectively (Tables 5, 7), suggesting the presence 
of promiscuous alleles, which further suggests that these sequence frames are 
potentially regulatory in nature and are predicted to bind to the DR4 allele (De 
Groot et al. 2008). More specifically, the αDEC-205:OVA-HC54-ORG (original) 
sequence contains 1 top 1% hit and 2-top 5% hits (Table 5). The sequence 
does contain a top 10% hit, which is considered to be non-significant and least 
likely to bind to the DR4 allele. The Tregitope αDEC-205:OVA-VH77-ORG 
(original) sequence (VH77-MOD1) contains 1 top 1% hit, 2-top 5% hits, and 1 
top 10% hit (non-significant) (Table 7).  
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Modification to the (22 amino acid-length) Tregitope αDEC-205:OVA-
HC54-MOD1 (HC54-MOD1) sequence involved the replacement of amino 
acids, leucine (position 4 & 11) and tyrosine (position 9), with all alanine amino 
acids. The resulting modifications to the HC54-MOD1 Tregitope sequence 
decreased the possible number of sequence frames likely to bind to the DR4 
allele, from three sequence frames to one (Table 10). The EpiMatrix z-score 
also decreased after subsequent modification, however, the single retained 
top 5% hit sequence frame suggests this sequence frame is still predicted to 
have a significant chance of binding to the DR4 allele, which could potentially 
inhibit effector, pro-inflammatory immune responses if presented and activates 
T cells (Table 6).  
In terms of the (23 amino acid-length) Tregitope VH77-ORG sequence, 
substitution of leucine (position 12) to alanine resulted in the VH77-MOD1 
Tregitope sequence and further substitution of tyrosine (position 6) to alanine 
resulted in the VH77-MOD2 Tregitope sequence. After modification to the 
VH77-ORG Tregitope sequence, the number of 9-mer frames predicted to 
bind to the DR4 allele decreased, similar to the HC54-ORG Tregitope 
sequence, from three sequence frames (ORG) to one top 1% hit-sequence 
frame within the VH77-MOD1 Tregitope sequence and zero frames in the 
VH77-MOD2 Tregitope sequence (Table 7-9). After modification, the EpiMatrix 
z-scores for all sequence frames relevant to the DR4 allele also decreased, 
similar to the HC54-ORG modification. However, in regards to the VH77-
MOD1 Tregitope sequence, there is still one sequence frame, after 
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modification, still predicted to bind to the DR4 allele. Though the EpiMatrix z-
scores decreased after modification, this sequence frame is still considered a 
top 1% hit and predicted to have an extremely likely chance of binding to the 
DR4 allele. The resulting VH77-MOD2, after modification, did not retain any 
sequence frames predicted to bind to the DR4 allele.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. The αDEC-205:OVA-HC54-ORG EpiMatrix Cluster 
Report analysis. Significant EpiMatrix z-scores ≥ 1.64 (hits), for all 
8 alleles, are highlighted in the medium blue and dark-blue colors. 
An EpiMatrix z-score indicates potential for that particular 9mer 
frame sequence to bind to a given HLA allele. There are three hits 
relevant to the DRB1*0401 allele and are predicted to bind, prior to 
modification. 
Frame Frame DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Start Stop Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score
54 PAVLQSDLY 62 0.32 0.45 -0.19 -0.06 -0.77 -1.45 -0.43 -0.48 -0.49 0 !0.5 0.76 1.16
55 AVLQSDLYT 63 0.42 -0.01 -0.64 0.93 -0.04 -0.12 0.49 0.24 1.07 0 !1.05 0.26 !1.06
56 VLQSDLYTL 64 0.64 0.3 1.38 0.02 1.07 0.36 0.86 0.89 1.48 0 !0.04 0.18 !0.84
57 LQSDLYTLS 65 0.09 1.69 2.13 1.79 0.33 0.83 -0.08 1.01 0.98 3 1.09 !0.45 0.44
58 QSDLYTLSS 66 -0.42 0.51 -0.52 1.22 -0.32 0.17 0.8 -0.13 -0.01 0 0.6 0.65 !0.82
59 SDLYTLSSS 67 -0.12 -1.33 -0.34 -0.84 -1.05 0.28 -0.14 0.89 0.68 0 !1.06 0.76 !1.84
60 DLYTLSSSV 68 0.43 0.96 -0.08 0.65 1.86 -0.02 -0.3 0.64 1.11 1 0.56 0.23 !2.42
61 LYTLSSSVT 69 0.74 1.87 0.22 1.55 1.84 1.04 1.25 0.34 1.8 3 0.34 1.01 !0.86
62 YTLSSSVTV 70 0.79 2.7 2.15 2.29 3.23 1.32 1.52 1.77 2.02 6 1.85 1.35 !0.59
63 TLSSSVTVP 71 0.76 -0.12 0.02 0.42 0.3 -0.55 -0.59 -0.31 -1.27 0 0.49 !0.35 0.21
64 LSSSVTVPS 72 0.74 1.86 2.25 2.33 1.33 1.24 1.38 1.88 1.39 4 1.12 0.18 !2.04
65 SSSVTVPSS 73 0.23 0.39 0.34 0.73 -0.36 0.34 1.04 0.64 0.21 0 0.4 2.25 !1.59
66 SSVTVPSST 74 0.24 0.25 -1.19 -0.1 0.71 -0.39 -0.79 -0.46 0.27 0 0.77 1.81 !1.68
67 SVTVPSSTW 75 0.23 -0.15 -0.23 -0.33 1.21 -1.11 -0.61 -0.11 0.28 0 0.6 !0.03 !1.82
DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501 Total
2.7 2.25 2.33 3.23 1.32 1.52 1.88 2.02 -- 1.85 2.25 1.16
8.12 6.54 6.42 6.93 0 0 3.65 3.82 35.48 1.85 4.06 !!
4 3 3 3 0 0 2 2 17 1 2 0
Top 10%* Top 5% Top 1%
     Sum of Significant Z scores
     Count of Significant Z Scores
Total Assessments Performed: 112 Hydrophobicity: 0.30 EpiMatrix Score: 23.94 EpiMatrix Score (w/o flanks): 23.94
AA Sequence Hydro-phobicity Hits
Summarized Results (04-NOV-2011)
     Maximum Single Z score
Scores Adjusted for Tregitope: -- EpiMatrix Score: 23.94 EpiMatrix Score (w/o flanks): 23.94
EpiMatrix Cluster Detail Report
I-AD
Z-Score
I-ED
Z-Score
November 04, 2011 (Epx Ver. 1.2)
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_CH_54_ORG Cluster: 54
I-AB 
Z-Score
  54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. The αDEC-205:OVA-CH54-MOD1 EpiMatrix Cluster 
Report analysis. Significant EpiMatrix z-scores ≥ 1.64 (hits), for all 
8 alleles, are highlighted in the medium blue and dark-blue colors. 
An EpiMatrix z-score indicates potential for that particular 9mer 
frame sequence to bind to a given HLA allele. After modification, 
there is a single 9mer sequence frame considered a top 5% hit 
that is predicted to have a significant chance of binding to the 
DRB1*0401 allele. 
 
Table 7. The αDEC-205:OVA-VH77-ORG EpiMatrix Cluster Report 
analysis. EpiMatrix z-scores ≥ 1.64 (hits), for all 8 alleles, are 
highlighted in the medium blue and dark-blue colors. An EpiMatrix z-
score indicates potential for that particular 9mer frame sequence to 
bind to a given HLA allele. There are three 9mer frame sequences 
predicted to bind to the HLA-DRB1*0401 allele. The frames 
highlighted in green are the conserved IgG sequences and are 
chosen for modification. 
 
Frame Frame DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Start Stop Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score
54 PAVLQSDLY 62 0.32 0.45 -0.19 -0.06 -0.77 -1.45 -0.43 -0.48 -0.49 0 !0.5 0.76 1.16
55 AVLQSDLYT 63 0.42 -0.01 -0.64 0.93 -0.04 -0.12 0.49 0.24 1.07 0 !1.05 0.26 !1.06
56 VLQSDLYTG 64 0.18 -0.03 1.18 0.23 -0.32 0.84 1.09 0.69 1.16 0 0.07 1.14 !0.74
57 LQSDLYTGS 65 -0.38 1.35 1.79 1.46 -0.01 0.48 -0.43 0.67 0.65 1 1.09 !1.04 !0.21
58 QSDLYTGSS 66 -0.89 0.21 -0.58 0.46 -0.41 0.1 0.32 -1.42 -0.3 0 0.63 0.41 !0.6
59 SDLYTGSSS 67 -0.59 -0.1 -0.6 0 -0.42 0.01 -0.4 0.64 0.68 0 !0.17 0.32 !1.1
60 DLYTGSSSV 68 -0.03 0.69 -0.35 0.39 1.6 -0.3 -0.58 0.37 0.85 0 0.56 !0.1 !1.95
61 LYTGSSSVT 69 0.28 0.97 0.26 0.99 1.18 0.03 0.26 -0.29 1.43 0 0.46 0.99 !1.4
62 YTGSSSVTV 70 0.32 2.41 1.86 2.02 2.95 1.02 1.23 1.49 1.74 5 2.27 1.68 !0.91
63 TGSSSVTVP 71 0.29 -0.65 -0.52 -0.1 -0.22 -1.11 -1.13 -0.84 -1.78 0 0.61 0.11 0.22
64 GSSSVTVPS 72 0.28 0.74 0.97 1.24 0.22 0.05 0.23 0.62 0.16 0 0.78 !0.35 !2.73
65 SSSVTVPSS 73 0.23 0.39 0.34 0.73 -0.36 0.34 1.04 0.64 0.21 0 0.4 2.25 !1.59
66 SSVTVPSST 74 0.24 0.25 -1.19 -0.1 0.71 -0.39 -0.79 -0.46 0.27 0 0.77 1.81 !1.68
67 SVTVPSSTW 75 0.23 -0.15 -0.23 -0.33 1.21 -1.11 -0.61 -0.11 0.28 0 0.6 !0.03 !1.82
DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501 Total
2.41 1.86 2.02 2.95 1.02 1.23 1.49 1.74 -- 2.27 2.25 1.16
2.41 3.65 2.02 2.95 0 0 0 1.74 12.77 2.27 5.74 !!
1 2 1 1 0 0 0 1 6 1 3 0
Top 10%* Top 5% Top 1%
November 04, 2011 (Epx Ver. 1.2)
Scores Adjusted for Tregitope: -- EpiMatrix Score: 1.24 EpiMatrix Score (w/o flanks): 1.24
     Sum of Significant Z scores
     Count of Significant Z Scores
Total Assessments Performed: 112 Hydrophobicity: 0.10 EpiMatrix Score: 1.24 EpiMatrix Score (w/o flanks): 1.24
AA Sequence Hydro-phobicity Hits
Summarized Results (04-NOV-2011)
     Maximum Single Z score
EpiMatrix Cluster Detail Report
I-AD
Z-Score
I-ED
Z-Score
I-AB 
Z-Score
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_CH_54_MOD1 Cluster: 54
Frame Frame DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Start Stop Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score
77 TQNILYLQM 85 0.17 0.73 -0.43 -0.04 0.52 -1.69 -0.12 0.08 0.54 0 0.23 1.42 '0.24
78 QNILYLQMN 86 -0.14 0.23 -0.3 -0.1 0.02 1.14 0.63 -1.26 0.54 0 '0.63 0.53 0.56
79 NILYLQMNS 87 0.16 -0.44 -0.62 -0.26 -0.67 0.71 0.44 -0.22 0.36 0 '1.71 '0.17 '1.07
80 ILYLQMNSL 88 0.97 1.69 1.38 1.21 1.92 1.29 1.56 0.81 1.61 2 '0.89 0.69 '0.36
81 LYLQMNSLR 89 -0.03 1.92 2.33 1.89 1.08 2.02 1.57 2.91 1.9 6 '1.2 '1.46 1.57
82 YLQMNSLRA 90 -0.26 3.3 2.01 3.41 2.9 2.23 3.43 1.97 2.82 8 1.6 1.42 '1.44
83 LQMNSLRAE 91 -0.5 0.03 1.72 0.08 0.03 1.89 1.52 1.24 0.33 2 0.72 '0.6 '0.33
84 QMNSLRAED 92 -1.31 -0.09 0.15 -0.98 -0.19 0.93 0.35 0.04 -0.82 0 0.26 '1.15 0.68
85 MNSLRAEDT 93 -1 2.01 0.53 1.62 1.66 1.39 1.52 0.29 1.42 2 1.15 1.21 '0.02
86 NSLRAEDTA 94 -1.01 -0.93 -1.69 -1.57 -1.3 -1.33 -0.87 -1.12 -1.51 0 '0.92 '0.8 '0.11
87 SLRAEDTAI 95 -0.12 0.04 0.87 0.44 0.43 -0.13 -1.17 0.84 1.12 0 '0.79 '0.65 '0.41
88 LRAEDTAIY 96 -0.18 1.23 1.7 1.66 -0.12 -0.47 0.85 1.67 -0.25 3 1.36 0.38 1.15
89 RAEDTAIYY 97 -0.74 -0.8 1.12 -0.21 -1.74 -1.64 -1.8 -0.01 -0.83 0 '0.56 1.13 '0.13
90 AEDTAIYYC 98 0.03 -2.15 -3.06 -1.99 -0.91 -1.81 -2.48 -2.32 -1.43 0 1.45 '0.26 '0.96
91 EDTAIYYCA 99 0.03 -0.42 -1.25 -0.71 -0.56 -1.29 -1.02 -1.37 -0.29 0 0.81 1.27 '0.32
DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501 Total
3.3 2.33 3.41 2.9 2.23 3.43 2.91 2.82 -- 1.6 1.42 1.57
8.92 7.76 6.96 6.47 6.14 3.43 6.55 4.71 50.94 '' '' ''
4 4 3 3 3 1 3 2 23 0 0 0
Top 10%* Top 5% Top 1%
     Sum of Significant Z scores
     Count of Significant Z Scores
Total Assessments Performed: 120 Hydrophobicity: -0.06 EpiMatrix Score: 38.59 EpiMatrix Score (w/o flanks): 38.59
AA Sequence Hydro-phobicity Hits
Summarized Results (04-NOV-2011)
     Maximum Single Z score
Scores Adjusted for Tregitope: -- EpiMatrix Score: -0.05 EpiMatrix Score (w/o flanks): -0.05
EpiMatrix Cluster Detail Report
I-AB 
Z-Score
I-AD
Z-Score
I-ED
Z-Score
November 04, 2011 (Epx Ver. 1.2)
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_VH_77_ORG Cluster: 77
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Table 8. The αDEC-205:OVA-VH77-MOD1 EpiMatrix Cluster Report 
analysis. EpiMatrix z-scores ≥ 1.64 (hits), for all 8 alleles, are 
highlighted in the medium blue and dark-blue colors. An EpiMatrix z-
score indicates potential for that particular 9mer frame sequence to 
bind to a given HLA allele. After modification, there is a single-9mer  
frame sequence considered a top 1% hit that is predicted to bind to 
the HLA-DRB1*0401 allele. 
Table 9. The αDEC-205:OVA-VH77-MOD2 EpiMatrix Cluster 
Report analysis. Significant EpiMatrix z-scores ≥ 1.64 (hits), for all 
8 alleles, if present, are highlighted in the medium blue and dark-
blue colors. An EpiMatrix z-score indicates potential for that 
particular 9mer frame sequence to bind to a given HLA allele. 
There are not any 9mer frame sequences predicted to bind to the 
DRB1*0401 allele, after modification. 
Frame Frame DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Start Stop Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score
77 TQNILYLQM 85 0.17 0.73 -0.43 -0.04 0.52 -1.69 -0.12 0.08 0.54 0 0.23 1.42 '0.24
78 QNILYLQMN 86 -0.14 0.23 -0.3 -0.1 0.02 1.14 0.63 -1.26 0.54 0 '0.63 0.53 0.56
79 NILYLQMNS 87 0.16 -0.44 -0.62 -0.26 -0.67 0.71 0.44 -0.22 0.36 0 '1.71 '0.17 '1.07
80 ILYLQMNSG 88 0.5 1.36 1.18 1.43 0.53 1.77 1.78 0.61 1.29 2 '0.78 1.65 '0.25
81 LYLQMNSGR 89 -0.5 1.58 1.99 1.56 0.74 1.66 1.22 2.57 1.57 3 '1.2 '2.06 0.91
82 YLQMNSGRA 90 -0.72 2.99 1.95 2.64 2.81 2.15 2.96 0.68 2.52 7 1.64 1.18 '1.21
83 LQMNSGRAE 91 -0.97 1.26 1.46 0.92 0.67 1.62 1.26 0.99 0.34 0 1.61 '1.04 0.42
84 QMNSGRAED 92 -1.78 -0.36 -0.12 -1.24 -0.46 0.65 0.07 -0.23 -1.08 0 0.26 '1.47 1.15
85 MNSGRAEDT 93 -1.47 1.11 0.58 1.05 0.99 0.37 0.52 -0.34 1.05 0 1.27 1.19 '0.56
86 NSGRAEDTA 94 -1.48 -1.21 -1.98 -1.85 -1.58 -1.63 -1.16 -1.41 -1.78 0 '0.5 '0.47 '0.43
87 SGRAEDTAI 95 -0.59 -0.49 0.34 -0.07 -0.09 -0.68 -1.71 0.32 0.61 0 '0.67 '0.19 '0.39
88 GRAEDTAIY 96 -0.64 0.1 0.41 0.57 -1.23 -1.65 -0.3 0.41 -1.48 0 1.01 '0.15 0.46
89 RAEDTAIYY 97 -0.74 -0.8 1.12 -0.21 -1.74 -1.64 -1.8 -0.01 -0.83 0 '0.56 1.13 '0.13
90 AEDTAIYYC 98 0.03 -2.15 -3.06 -1.99 -0.91 -1.81 -2.48 -2.32 -1.43 0 1.45 '0.26 '0.96
91 EDTAIYYCA 99 0.03 -0.42 -1.25 -0.71 -0.56 -1.29 -1.02 -1.37 -0.29 0 0.81 1.27 '0.32
DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501 Total
2.99 1.99 2.64 2.81 2.15 2.96 2.57 2.52 -- 1.64 1.65 1.15
2.99 3.94 2.64 2.81 5.58 4.74 2.57 2.52 27.79 1.64 1.65 ''
1 2 1 1 3 2 1 1 12 0 1 0
Top 10%* Top 5% Top 1%
     Maximum Single Z score
November 04, 2011 (Epx Ver. 1.2)
Scores Adjusted for Tregitope: -- EpiMatrix Score: 15.45 EpiMatrix Score (w/o flanks): 15.45
     Sum of Significant Z scores
     Count of Significant Z Scores
Total Assessments Performed: 120 Hydrophobicity: -0.24 EpiMatrix Score: 15.45 EpiMatrix Score (w/o flanks): 15.45
AA Sequence Hydro-phobicity Hits
Summarized Results (04-NOV-2011)
EpiMatrix Cluster Detail Report
I-AB 
Z-Score
I-AD
Z-Score
I-ED
Z-Score
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_VH_77_MOD1 Cluster: 77
Frame Frame DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Start Stop Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score
77 TQNILALQM 85 0.51 1.16 0.43 1.03 0.98 -0.8 0.75 0.92 0.94 0 0.89 2.01 '0.29
78 QNILALQMN 86 0.2 0.16 -0.37 -0.17 -0.05 1.06 0.56 -1.33 0.47 0 '0.63 '0.14 0.27
79 NILALQMNS 87 0.5 0.46 0.56 0.58 -0.21 0.67 0.78 -0.4 0.51 0 '0.87 0.37 '1.22
80 ILALQMNSG 88 0.84 1.5 1.33 1.57 0.68 1.92 1.94 0.76 1.43 2 '0.46 1.74 '0.03
81 LALQMNSGR 89 -0.16 1.32 1.72 1.3 0.48 1.38 0.95 2.31 1.31 2 '1.26 '2.25 0.52
82 ALQMNSGRA 90 -0.38 1.53 0.89 1.22 1.37 0.62 1.46 -0.36 1.51 0 0.4 0.82 '1.73
83 LQMNSGRAE 91 -0.97 1.26 1.46 0.92 0.67 1.62 1.26 0.99 0.34 0 1.61 '1.04 0.42
84 QMNSGRAED 92 -1.78 -0.36 -0.12 -1.24 -0.46 0.65 0.07 -0.23 -1.08 0 0.26 '1.47 1.15
85 MNSGRAEDT 93 -1.47 1.11 0.58 1.05 0.99 0.37 0.52 -0.34 1.05 0 1.27 1.19 '0.56
86 NSGRAEDTA 94 -1.48 -1.21 -1.98 -1.85 -1.58 -1.63 -1.16 -1.41 -1.78 0 '0.5 '0.47 '0.43
87 SGRAEDTAI 95 -0.59 -0.49 0.34 -0.07 -0.09 -0.68 -1.71 0.32 0.61 0 '0.67 '0.19 '0.39
88 GRAEDTAIY 96 -0.64 0.1 0.41 0.57 -1.23 -1.65 -0.3 0.41 -1.48 0 1.01 '0.15 0.46
89 RAEDTAIYY 97 -0.74 -0.8 1.12 -0.21 -1.74 -1.64 -1.8 -0.01 -0.83 0 '0.56 1.13 '0.13
90 AEDTAIYYC 98 0.03 -2.15 -3.06 -1.99 -0.91 -1.81 -2.48 -2.32 -1.43 0 1.45 '0.26 '0.96
91 EDTAIYYCA 99 0.03 -0.42 -1.25 -0.71 -0.56 -1.29 -1.02 -1.37 -0.29 0 0.81 1.27 '0.32
DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501 Total
1.53 1.72 1.57 1.37 1.92 1.94 2.31 1.51 -- 1.61 2.01 1.15
0 1.72 0 0 1.92 1.94 2.31 0 7.89 '' 3.75 ''
0 1 0 0 1 1 1 0 4 0 2 0
Top 10%* Top 5% Top 1%
     Count of Significant Z Scores
Total Assessments Performed: 120 Hydrophobicity: -0.11 EpiMatrix Score: -4.47 EpiMatrix Score (w/o flanks): -4.47
AA Sequence Hydro-phobicity Hits
Summarized Results (04-NOV-2011)
     Maximum Single Z score
     Sum of Significant Z scores
Scores Adjusted for Tregitope: -- EpiMatrix Score: -4.47 EpiMatrix Score (w/o flanks): -4.47
EpiMatrix Cluster Detail Report
I-AB 
Z-Score
I-AD
Z-Score
I-ED
Z-Score
November 04, 2011 (Epx Ver. 1.2)
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_VH_77_MOD2 Cluster: 77
 56 
 
 
 
 
 
 
 
 
 
Antibodies Cluster Address Cluster Sequence 
HLA-
DRB1*0401 
EpiMatrix Hits  
Produced 
αDEC-205:HC54-
ORG 54-75 PAVLQSDLYTLSSSVTVPSSTW 3 YES 
αDEC-205:HC54-
MOD1 54-75 PAVAQSDLATASSSVTVPSSTW 1 YES 
αDEC-205:HC54-
MOD2 54-75 PAVAQSDLATASQSVTVPSSTW 0 NO 
αDEC-205:VH77-
ORG 77-99 TQNILYLQMNSLRAEDTAIYYCA 3 YES 
αDEC-205:VH77-
MOD1 77-99 TQNILYLQMNSGRAEDTAIYYCA 1 YES 
αDEC-205:VH77-
MOD2 77-99 TQNILALQMNSGRAEDTAIYYCA 0 YES 
αDEC-205:VH77-
MOD3 77-99 TQNIGALQMNSGRAEDTAIYYCA 0 NO 
 
Table 10. Potential Tregitope sequences selected for modification. Non-
modified and modified predicted Tregitope sequences showing the number 
of epitope sequence frames predicted to bind to the HLA-DRB1*0401 
allele. The table also shows which sequences were successfully expressed 
into recombinant protein. 
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Protein Purification 
 In total, recombinant expression of six variant αDEC-205:OVA 
antibodies was attempted, however only three of the six variant antibodies 
were successfully expressed. The other three variant antibodies showed either 
no or low expression levels, which suggested that the epitope modifications 
performed were deleterious to the structure. Purified recombinant protein was 
determined via gel electrophoresis analyses, which showed the presence of 
strong bands at the predicted molecular weights for a single light (25 kD) and 
a single heavy chain attached to ovalbumin (95 kD) (Ito et al. 1996, Janeway 
et al. 2001, Sun et al. 2010). The resulting recombinant antibodies 
successfully expressed were αDEC-205:OVA-HC54-MOD1, αDEC-205:OVA-
VH77-MOD1, and αDEC-205:OVA-VH77-MOD2 (Table 10).  
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LC 
HC 
       Load FT Wash Elute2  Load FT Wash Elute2 
Figure 8. A gel electrophoresis image showing the purity check points 
taken during protein purification. A sample of protein supernatant is 
taken prior to purification, during purification over protein G column, 
wash through, and the final eluting of the concentrated sample’s heavy 
and light chain. The expected molecular weight of a single heavy chain 
attached to Ovalbumin is 95 kD. The molecular weight of a single light 
chain is 25 kD.  
αDEC-205:OVA-ORG     αDEC-205:OVA-HC77-MOD1
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Figure 10. A gel electrophoresis image showing the correct or partial 
production of the variant αDEC-205:OVA antibodies. Mutant antibodies, 
HC54-MOD1, VH77-MOD1, VH77-MOD2, were produced correctly during 
transfection, where as, mutant antibodies HC54-MOD2, VH77-MOD3, and 
VH77-HC54 were only partially produced due to lack of heavy chain 
presence on the gel. .  
WT Mut 1 Mut 3 Mut 4 
HC 
LC 
WT = αDEC-205-ORG Mut 1= HC54-MOD1 Mut 3= HC77-MOD1  
Mut 4= HC77-MOD2     
Figure 9. A gel electrophoresis image showing the production 
of wild type and modified αDEC-205 antibodies. 
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Dendritic Cell Binding Assay 
 Using the flow cytometer analysis software (BD FACs Diva V8.0) DC 
subsets negative for the CD11c+ marker (DC lineage marker) were gated on to 
establish the negative control DC population (Figure 11). Further selective 
gating for the αIgG-FITc staining antibody was performed. Any DCs migrating 
from the initial negative control population to the “CD11c+ αIgG-FITC+ ” 
labeled quadrant indicates double positive DC staining (Figure 12). Migration 
into the double positive quadrant further indicates αDEC-205:OVA antibodies 
(ORG and variant) are present and targeting the DEC-205 receptor, within 
their respective samples.  
The negative control JAWS II DC population was not pulsed with any 
antibody, but was stained with the αIgG-FITc antibody. However, 3.3% of the 
CD11c+ DCs were shown to have positive staining for the αIgG-FITc antibody. 
This suggests that the αIgG-FITc antibody is capable of non-specifically 
binding to DCs. That non-specific binding percentage was then subtracted 
from all resulting positive binding data. As for the DCs that were pulsed with 
the αIso:OVA antibody, similar results to the negative control are observed. 
Only 3.1% of the JAWS II CD11c+ DC total population are targeted by the non-
specific antibody and positively stained with the αIgG-FITc antibody (Figure 
11).  
The column graph (Figure 13) demonstrates that all three variant 
antibodies (HC54-MOD1, VH77-MOD1, VH77-MOD2) and the αDEC-
205:OVA-ORG antibody have very similar targeting capacities for the DEC-
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205 receptor. 60-65% of the total JAWS II CD11c+ DC population were 
targeted by the variant αDEC-205:OVA antibodies, whereas 59% of the DC 
population was targeted by the αDEC-205:OVA-ORG antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. A DC binding assay negative control density plot 
showing only JAWS II CD11c+ DCs. There is no positive 
staining for the αIgG-FITc antibody, which only targets IgG 
molecules. 
Figure 12. A DC binding assay positive control density plot 
showing JAWS II CD11c+ DCs pulsed with αDEC-205:OVA. 
The main population of JAWS II DCs migrate from the initial 
“Q3” quadrant to the right as is expected for αIgG-FITc 
positively stained DCs.   
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Figure 13. A dendritic cell binding assay column graph depicting the 
percentage of JAWS II CD11c+ αIgG-FITc+ DCs. Flow cytometer data of 
the percentage of JAWS II CD11c+ αIgG-FITc+ DCs is taken for each 
sample and formatted in a column graph output. All αDEC-205:OVA 
antibodies (ORG and variant) showed similar targeting capacities to the 
DCs’ DEC-205 receptors.  
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Dendritic Cell Binding Assay 
JAWS II Cells: CD11c+αΙgG-FITC+ 
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In vivo Immunizations 
HLA-DR4 mice were immunized with control and modified antibodies 
(HC54-MOD1, VH77-MOD1, VH77-MOD2), both with and without a maturation 
factor (αCD40) and IFN-γ secretion and antigen-specific T cell expansion were 
measured to characterize a pro-inflammatory immune response using an ex 
vivo ELISpot assay and a T cell proliferation memory response assay (Tacken 
et al. 2007, Hochrein et al. 2001, Letsch et al. 2003).  
 
Ex vivo ELISpot Assay Results 
Splenocytes previously immunized with the αDEC-205:OVA-ORG 
antibody and agonistic αCD40, after re-stimulation with the OVA class I 
peptide (257-264), elicited significant OVA-specific CD8+ T cell immune responses 
as defined by IFN-γ secretion. Splenocytes immunized with the αDEC-
205:OVA-ORG antibody alone secreted significantly less IFN-γ overall with 
12.9 spots on average per mouse subject in comparison to 2404.5 spots on 
average for mice treated with αDEC-205:OVA-ORG (Mann-Whitney U test 
analysis, p-value < 0.0001) (Figure 14). The same result was obtained (p 
value ≤ 0.0001) when comparing the IFN-γ responses generated by 
splenocytes immunized with the αDEC-205:OVA-ORG antibody + αCD40 
condition and splenocytes immunized with the non-specific, non-targeting 
αIsotype:OVA + αCD40 condition (Figure 14). Splenocytes from mice 
immunized with αDEC-205:OVA-HC54-MOD1, αDEC-205:OVA-VH77-MOD1, 
and αDEC-205:OVA-VH77-MOD2 antibodies produced similar levels of IFN-γ 
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when re-stimulated with OVA Class I (257-264) (p > 0.05) than the splenocytes 
from mice immunized with αDEC-205:OVA-ORG (Figure 15). This suggests 
the variant αDEC-205:OVA antibodies, though modified, failed to activate 
antigen-specific T cells at greater levels than the αDEC-205:OVA-ORG 
immunized splenocytes.  
 Another experiment was done using the OVA Class II peptide (323-339) to 
re-stimulate  splenocyte cultures. This peptide tested for OVA specific CD4+ T 
cell activation. However, all mice immunization conditions failed to elicit a 
memory recall response characterized by IFN-γ secretion, including the 
positive control (αDEC-205:OVA antibody + CD40). This result is unexpected 
because this peptide is predicted to bind to the HLA-DRB1*0401 allele. 
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Figure 14. Splenocyte IFN-γ Secretion: OVA 257-264 Re-
stimulation: Control Plot. This control plot shows 
statistically significant elevated IFN-γ responses from 
splenocytes immunized with the αDEC-205:OVA + 
αCD40 immunization condition than splenocytes 
immunized with αDEC-205:OVA-ORG or αISO:OVA + 
αCD40 (Mann-Whitney U test; p< 0.0001).  
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Figure 15. Splenocyte IFN-γ Secretion: OVA 257-264 
Re-stimulation: Experimental Plot. This experimental 
plot shows that splenocytes immunized with either 
variant αDEC-205:OVA antibodies did not elicit higher 
elevated IFN-γ responses than splenocytes 
immunized with the non-modified αDEC-205:OVA 
immunization condition. (Mann-Whitney U test; 
p>0.05).  
 67 
Ex vivo T cell Proliferation Assay 
The T cell proliferation assay was performed to test if ovalbumin-
specific CD4+ and CD8+ T cell expansion occurred in response to 
immunization with the variant antibodies. Significantly more CD4+ and CD8+ T 
cell expansion occurred with αDEC-205:OVA antibody combined with the 
αCD40 co-stimulatory signal, compared to the weak proliferation levels for 
both CD4+ and CD8+ T cell populations when mice were immunized with the 
αDEC-205:OVA-ORG antibody alone (Mann-Whitney U test; p<0.0001; 
Figures 16,18). Minimal T cell proliferation was observed when the non-
specific, non-targeting control antibody plus maturation factor were used in 
immunizations (p-value = 0.003 (CD4), p>0.0001(CD8)) (Figures 16,18).  
 Immunization of mice with variant antibodies, αDEC-205:OVA-HC54-
MOD1 and αDEC-205:OVA-VH77-MOD1 did not lead to statistically higher 
CD4+ T cell proliferation percentages in splenocytes than splenocytes 
immunized with αDEC-205:OVA-ORG (p>0.05; Figure 19). However, mice 
immunized with αDEC-205:OVA-VH77-MOD1 (but not αDEC-205:OVA-HC54-
MOD1) showed significantly higher CD8+ T cell proliferation when compared 
to the αDEC-205:OVA-ORG immunization (p<0.05; Figure 17).  
Mice immunized with the αDEC-205:OVA-VH77-MOD2 immunization 
condition did generate statistically higher CD4+ T cell proliferation percentages  
than splenocytes immunized with αDEC-205:OVA-ORG (p<0.05; Figure 19). 
However, the αDEC-205:OVA-HC54-MOD1 and αDEC-205:OVA-VH77-MOD2 
immunized splenocytes did not elicit statistically significant CD8+ T cell 
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proliferation percentages in comparison to splenocytes immunized with αDEC-
205:OVA-ORG (p>0.05; Figure 17).  
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Figure 16. CD8+ T cell Proliferation: Ovalbumin Re-
stimulation Control Plot. This control plot shows 
statistically higher and significant CD8+ T cell 
proliferation percentages from splenocytes 
immunized with the αDEC-205:OVA + αCD40 
immunization condition than splenocytes immunized 
with αDEC-205:OVA-ORG or αISO:OVA + αCD40 
(Mann-Whitney U test; p< 0.0001).  
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Figure 17. CD8+ T cell Proliferation: Ovalbumin Re-
stimulation Experimental Plot. This experimental plot 
shows statistically higher and significant CD8+ T cell 
proliferation percentages from splenocytes 
immunized with the αDEC-205:OVA-VH77-MOD1 
immunization condition than splenocytes immunized 
with αDEC-205:OVA-ORG (Mann-Whitney U test; p< 
0.0001). Splenocytes immunized with the αDEC-
205:OVA-HC54-MOD1 and αDEC-205:OVA-VH77-
MOD2 did not elicit statistically higher CD8+ T cell 
proliferation percentages than splenocytes 
immunized with αDEC-205:OVA-ORG (p>0.05). 
 71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aD
EC
-20
5:O
VA
-O
RG
aD
EC
-20
5:O
VA
-O
RG
 + 
aC
D4
0
aIS
O:
OV
A +
 aC
D4
0
0.0
0.5
1.0
1.5
2
3
4
Control Plot
T 
ce
ll P
ro
lif
er
at
io
n 
Pe
rc
en
ta
ge
s 
(a
bo
ve
 b
kg
rd
) CD4 + T cell Proliferation
Ovalbumin Re-stimulation
**** **
Figure 18. CD4+ T cell Proliferation: Ovalbumin Re-
stimulation Control Plot. This control plot shows 
statistically higher and significant CD4+ T cell 
proliferation percentages from splenocytes immunized 
with the αDEC-205:OVA + αCD40 immunization 
condition than splenocytes immunized with αDEC-
205:OVA-ORG or αISO:OVA + αCD40 (Mann-Whitney 
U test; p< 0.0001 (ORG), p= 0.003 (ISO:OVA)).  
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Figure 19. CD4+ T cell Proliferation: Ovalbumin Re-
stimulation Experimental Plot. This experimental plot 
shows statistically higher and significant CD4+ T cell 
proliferation percentages from splenocytes immunized 
with the αDEC-205:OVA-VH77-MOD2 immunization 
condition than splenocytes immunized with αDEC-
205:OVA-ORG (Mann-Whitney U test; p<0.05). 
Splenocytes immunized with the αDEC-205:OVA-
HC54-MOD1 and αDEC-205:OVA-VH77-MOD1 did 
not elicit statistically higher CD4+ T cell proliferation 
percentages than splenocytes immunized with αDEC-
205:OVA-ORG (p>0.05). 
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CHAPTER 5 
 
DISCUSSION 
Overall, three modified antibodies (αDEC-205:OVA-HC54-MOD1, 
αDEC-205:OVA-VH77-MOD1, αDEC-205:OVA-VH77-MOD2) were 
successfully expressed and administered in in vivo immunizations to HLA-DR4 
mice. Data from the in vivo immunizations indicated that statistically higher T 
cell proliferation was observed from splenocytes immunized with αDEC-
205:OVA-VH77-MOD1 (CD8+ T cells) and αDEC-205:OVA-VH77-MOD2 
(CD4+ T cells) than splenocytes immunized with the non-modified αDEC-
205:OVA-ORG immunization condition. However, the data indicated that there 
was not a statistically elevated IFN-γ response from the splenocytes 
immunized with any of the three variant αDEC-205:OVA antibodies in 
comparison to the non-modified αDEC-205:OVA-ORG immunized 
splenocytes. No statistically significant elevated responses characteristic of an 
effector immune response was reported for splenocytes immunized with the 
αDEC-205:OVA-HC54-MOD1 immunization condition. Overall, this data 
suggests that the modifications to the potential VH77 Tregitope sequence lead 
to a decrease in antibody tolerogenicity and resulted in a potentially novel and 
increased immunogenic vaccine antigen delivery vehicle.  
Our results that the αDEC-205:OVA monoclonal antibody is an effective 
delivery vehicle selectively targeting APCs for ovalbumin-antigen presentation 
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to CD4+ and CD8+ T cells confirmed previous findings presented by Bonifaz et 
al. 2004 and Tacken et al. 2007. Generally, antigen targeted to the DEC-205 
receptor is trafficked to the MHC II presentation pathway where MHC II 
molecules present antigenic peptides to CD4+ T cells specifically. This work 
provides evidence that when the αDEC-205:OVA-VH77-MOD2 antibody 
targets the DEC-205 receptor, the receptor’s bias towards CD4+ T cells is 
showcased, which is due to the proximal and distal regions of the DEC-205 
receptor’s cytosolic tail, which targets late endosomal vesicles containing MHC 
II molecules (Figure 19) (Tacken et al. 2007, Steinman et al. 2000, Lahoud et 
al. 2012, Mahnke et al. 2000, Harding et al. 2010) This work also provides 
further evidence, initially reported by Bonifaz et al. 2004, that though the DEC-
205 receptor is biased towards the MHC II pathway, that targeting the DEC-
205 receptor can also  traffic antigen to MHC I molecules for CD8+ T cell 
presentation, in which our results show the use of  αDEC-205:OVA-VH77-
MOD1 during in vivo immunizations results in CD8+ T cell proliferation after 
splenocytes have been re-stimulated with either OVA (257-264) or ovalbumin 
(Figures 14-17). Due to the occurrence of CD8+ T cell proliferation in our 
results, this suggests that cross presentation is occurring, which is the process 
in which antigenic peptides make their way out into the cytosol for proteasomal 
degradation and are then taken back into the lumen of the Endoplasmic 
Reticulum for peptide loading onto MHC I molecules and take part in the MHC 
I pathway (Steinman et al. 2000, Janeway et al. 2001).  
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We found that immunization of mice with antibodies in which 
modifications to the VH77 Tregitope sequence, located in the variable region 
of the heavy chain (Table 10) (αDEC-205:OVA-VH77-MOD1 and αDEC-
205:OVA-VH77-MOD2), led to significantly higher levels of  CD8+ and CD4+ T 
cell proliferation (respectively) than mice immunized with the antibody 
containing unmodified Tregitopes, suggesting that the point mutations lowered 
the tolerogenicity level of the antibody and increased the antibody’s 
immunogenicity allowing for a potential effector immune response, 
characterized by T cell proliferation and IFN-γ secretion, to ensue. This further 
suggests that the potential Tregitope effect was fully knocked out and allowed 
for the proverbial “immunological balance” with tolerance on one arm of the 
scale and immunogenicity on the other, to shift towards immunogenicity. 
Therefore, enabling the αDEC-205:OVA-VH77-MOD1 or αDEC-205:OVA-
VH77-MOD2 targeting antibodies to induce a potential pro-inflammatory 
immune response without the need for a maturation factor or co-stimulatory 
molecule (Moise et al. 2012, De Groot et al. 2008).  
However, the modified antibodies (VH77-MOD1 and VH77-MOD2) 
immunized splenocytes did not induce statistically elevated IFN-γ responses. 
Overall, an elevated IFN-γ response per se was not expected to occur. 
Though IFN-γ does not need to be seen at elevated levels to indicate an 
immune response, it could still be seen as an indicator that further cytokine 
presence should be analyzed to determine if there is a cytokine during 
antigen-re-stimulation that is prevalent above all other cytokines. For instance, 
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cytokines such as IL-2, IL-4, IL-12, and TNF-α or IL-10, and TGF-β could be 
reviewed in culture supernatants to identify the type of immune response that 
is being induced by these variant antibodies during ex vivo culture and re-
stimulation of splenocytes (Steinman et al 2000, De Groot et al. 2008, 
Cousens et al. 2013).  
Splenocytes from all of the immunized conditions were treated to not 
only OVA (257-264), but also OVA (323-339) during the ELISpot assay; however, the 
splenocytes treated with OVA (323-339) failed to become activated and thus did 
not secrete IFN-γ. OVA (323-339) is a class II peptide (Table 4) that can be found 
within ovalbumin, the whole protein, that was conjugated to the αDEC-205 
antibody and administered to the DR4 mice during in vivo immunizations. 
Thus, if the ovalbumin had been processed and degraded into peptides by the 
acid proteases (Cathepsins S & L) within the acidic endosomal/lysosomal 
vesicles, then it is possible that OVA (323-339) could have been generated 
through this degradation process. Then OVA (323-339) would be presented by 
MHC molecules to circulating T cells for the subsequent activation and 
induction of a protective immune response. Some of the potential effector T 
cells generated from the initial immune response then differentiate into 
memory T cells. Memory T cells, upon recognition of the same OVA (323-339) 
antigen, are then able to rapidly turn into effector T cells once again and 
induce an accelerated antigen-specific T cell mediated immune response. 
However, because IFN-γ was not secreted after re-stimulation with OVA (323-
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339) that suggests that the initial breakdown of ovalbumin into peptides during 
in vivo immunizations did not generate OVA (323-339) for presentation to T cells.  
Since CD4+ T cell proliferation was observed in the T cell proliferation 
assay, this means that class II peptides can be presented to T cells and T cells 
are able to subsequently recognize the peptide, bind to the complex, and 
initiate proliferation. This result is suggesting that there are potentially other 
class II peptides within ovalbumin that can be presented to T cells and induce 
an immune response. This is definitely possible because the initial in silico 
prediction of OVA (323-339) binding potential was 1.66. A score of 1.64 or greater 
is required for any sequence frame to have a significant chance of binding to a 
given HLA allele. Thus, because the OVA (323-339) sequence had an EpiMatrix 
z-score of 1.66, it is considered a top 5% hit, but it is on the EpiMatrix z-score 
significance level threshold, which suggests there is potential for this 
sequence to be a false positive binder to the DR4 allele. An HLA-DR4 binding 
assay that would test the strength of the OVA (323-339) binding potential to the 
DR4 allele would be required to confirm a false positive binding theory. 
Furthermore, because of the possibility for OVA (323-339) to be a false positive 
binder to the DR4 allele, it is therefore possible that even if the sequence was 
generated during proteolytic processing of ovalbumin, an immune response 
would not be generated. An additional issue to consider as to why a lack of 
immune response was generated after OVA (323-339) was assayed is that the 
working stock solution that was used potentially could have been unstable and 
degraded. Generally, this can occur due to repeated “freeze-thaw cycles”, 
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which can also lead to loss of stability (Nowatzke et al. 2003). However, 
measures were taken prior to peptide usage in immunogenicity assays to 
counteract such instances, such as aliquoting the solvated peptide in usable 
volumes.  
As for the αDEC-205:OVA-HC54-MOD1 immunization condition, no 
statistically elevated levels of  T cell proliferation or IFN-γ secretion was 
observed. Splenocytes immunized with this particular variant antibody 
generated data similar to the αDEC-205:OVA-ORG immunization condition. 
This variant antibody was generated by modifying the constant heavy chain 
region and is not associated with the variable heavy chain (VH77) Tregitope 
sequence (Figure 7). Possible reasons why pro-inflammatory immune 
response characteristics were not observed for the αDEC-205:OVA-HC54-
MOD1 immunization condition at statistically elevated levels in comparison to 
the non-modified αDEC-205:OVA-ORG immunization condition are that it may 
not be the most tolerogenic Tregitope sequence or it may not have been fully 
deleted for an effector (pro-inflammatory) immune response to take hold. 
Unpublished reports (from De Groot et al.) indicate the human Tregitope 
sequence (Hu84) (mouse equivalent to VH77) is the most tolerogenic out of 
the three potential Tregitope sequences (Hu84, Hu167, Hu289). Therefore, if a 
pro-inflammatory immune response were to occur, it would have been 
expected when the αDEC-205:OVA-VH77 (MOD1 and MOD2) antibodies 
were used in immunizations, due to modifications to the VH77 Tregitope 
sequence, which is what we observed in T cell proliferation measurements. 
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However, published reports from De Groot et al. 2008 identified two other 
strong epitope clusters, Hu167 and Hu289. The same EpiMatrix suite of in 
silico tools used in this research project were used to identify these potential 
tolerogenic T cell epitopes, which showcased EpiBars (band-like patterns) or 
dense populations of epitope hits against a panel of eight class II alleles 
representative of highly promiscuous and potentially immunodominant 
epitopes that showed homology to human immunoglobulin. These T cell 
epitope sequences were found to rank highly on the human immunogenicity 
scale (De Groot et al. 2008, Cousens et al. 2013).  
De Groot et al. 2008 demonstrated the effectiveness of the human 
Tregitope sequence Hu167, homologous to murine Tregitope sequence HC54, 
to induce a 2-fold increase in CD4+CD25+FoxP3+ T cells after Tregitope 
stimulation (including Hu289) to PBMCs, which had suggested the activation 
of Tregs and confirmed the expected activity of Tregitopes. Further, studies 
performed by Cousens et al. 2013 using the murine Tregitope equivalents to 
human Tregitopes Hu167 and Hu289 showed similar T regulatory cell 
activation and effector immune response suppression in non-obese diabetic 
mice (NOD). Furthermore, Tregitope activity with the co-administration of Type 
1 diabetes antigen was shown to delay the onset of hyperglycemia and reduce 
the incidence rate in non-obese diabetic mice (NOD), as well as suppress the 
effects of diabetes after development in NOD mice (Cousens et al. 2013).  
Previous research has demonstrated that these Tregitope sequences 
can generate Treg cells. Modifications to the single HC54 epitope sequence 
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tested here may not have been enough to overcome the tolerogenicity level of 
an antibody containing the other two potential highly tolerogenic Tregitope 
sequences (Hu84 (mouse VH77) and Hu289). Further evidence that more 
extensive modification is required, when the “highest” tolerogenic Tregitope 
sequence is not targeted for modification, is the presence of potential 
regulatory sequence frames. Even after modifications, the αDEC-205:OVA-
HC54-MOD1 antibody retained one sequence frame predicted to have a 
significant chance of binding to the HLA-DR4 allele. De Groot et al. previously 
demonstrated the effectiveness of the human and murine Tregitope 
sequences to induce Treg cells with Tregitope stimulation; therefore, it is 
possible with one sequence frame still predicted to bind to the DR4 allele in 
the HC54 Tregitope sequence, that the full Tregitope effect has not been 
knocked out and if the sequence is presented it could activate Tregs (De Groot 
et al. 2008, De Groot et al. 2013). An HLA-DR4 binding assay could be 
performed to confirm whether the Tregitope sequences are positive binders, 
which could suggest the potential likelihood for Tregitope presentation and 
Treg cell activation. 
Overall, this study provided data that suggests modifying specific 
Tregitope sequences within the αDEC-205:OVA antibody is capable of 
rendering the antibody less tolerogenic, allowing for the induction of 
statistically significant levels of pro-inflammatory immune responses after 
antigen re-stimulation. Consequently, the information provided by this study 
could add to the vaccination strategy repertoire and become a viable option to 
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consider when utilizing therapeutic antibodies as a means for immunotherapy 
in regards to autoimmunity, tumors, and potentially HIV and cancer. However, 
the big issue plaguing most therapeutic antibodies is the immune response 
generated by the antibody and associated biologic proteins that can interfere 
with treatment efficacy due to anti-drug antibodies (De Groot et al. 2013). 
Therefore, it would be necessary to confirm the immunogenicity of the 
antibody first prior to use in clinical studies. However, this potentially improved 
vaccine delivery platform system may be most efficient as a vaccination 
strategy prior to infection since immunity against specific pathogens could be 
garnered by coupling specific antigens to the targeted therapeutic antibody to 
generate immune system recognition and lead to memory.      
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CHAPTER 6 
 
CONCLUSION 
By harnessing the innate ability of the DEC-205 receptor, found 
ubiquitously on DCs, to ingest pathogen, process it, and present its antigenic 
peptides to T cells, it has become a viable candidate for novel targeted 
vaccination strategies. The overall goal of this study was to create an 
improved vaccine delivery system by modifying regulatory T cell epitopes 
found within the αDEC-205:OVA antibody’s sequence. These modifications 
would in turn generate newly de-tolerized monoclonal antibodies capable of 
targeting the DEC-205 receptor and serve as delivery vehicles for vaccine test 
antigens to raise a robust antigen-specific T cell mediated protective immune 
responses.  
Two monoclonal antibodies stood out amongst the three total variant 
antibody sequences, the αDEC-205:OVA-VH77-MOD1 and αDEC-
205:OVAVH77-MOD2 antibody. The αDEC-205:OVA-VH77-MOD1 retained 
one predicted and potential regulatory sequence frame predicted to bind to the 
DR4 allele, while the αDEC-205:OVA-VH77-MOD2 antibody did not retain any 
potential regulatory sequence frames predicted to bind. However, when both 
antibody sequences (VH77-MOD1 and VH77-MOD2) were administered in in 
vivo immunizations, without co-stimulatory factors, CD8+ and CD4+ T cell 
proliferation was induced, respectively. These results were statistically 
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significant when compared to the baseline levels of the non-modified αDEC-
205:OVA-ORG antibody immunized splenocytes.  
 An improved novel targeted vaccination strategy, raising antigen-
specific immune responses, is underway and the successful first steps have 
been taken. The next steps to take would be to perform studies that further 
establish what types of T cells are proliferating. These studies have given 
initial estimates that the T cells that are proliferating are potentially effector in 
nature due to IFN-γ secretion; however, further application of splenocytes in T 
cell proliferation and phenotyping assays, from more in vivo immunizations, 
will assess if the T cells present and proliferating are effector or regulatory in 
nature due to the application of intracellular staining. Intracellular staining can 
confirm the T cell phenotype established by extracellular staining based on the 
identification of transcription factors, present after antigen re-stimulation, 
associated with either effector or regulatory immune responses.  
It would be interesting to see whether levels of Treg expression 
increased when comparing all four antibodies (ORG and three variants) 
against one another. Higher Treg expression would be expected with the 
αDEC-205:OVA-ORG (no Tregitope modification) and αDEC-205:OVA-HC54-
MOD1 (no statistically significant data) conditions. Whereas, Treg cell levels 
would be expected to decrease when the αDEC-205:OVA-VH77-MOD1 and 
αDEC-205:OVA-VH77-MOD2 conditions are used and subsequent T cell 
proliferation is phenotyped.  
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Also, further site directed mutagenesis work could be performed to the 
αDEC-205:OVA-VH77-MOD2 antibody. This process would be performed 
again to determine if further modification to additional Tregitope sequences to 
αDEC-205:OVA-VH77-MOD2 antibody imparted further reduction in tolerance 
and increased expression of pro-inflammatory immune responses.  
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